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Abstract 
Background 
The hominid-specific non-LTR retrotransposon termed SINE VNTR Alu (SVA) is the youngest 
of the transposable elements in the human genome. The propagation of the most ancient SVA type 
A took place about 13.5 Myrs ago, and the youngest SVA types appeared in the human genome after 
the chimpanzee divergence. There are about 2700 insertions of the SVAs in human genome that are 
responsible for gene structural polymorphisms and modulation of gene expression, however 
functional and evolutionary significance of these insertions is not clear.  
Results 
Functional enrichment analysis of genes associated with SVA insertions demonstrated their 
link to multiple ontological categories attributed to brain function and the disorders.  Moreover, SVA 
types that expanded their presence in the human genome at different stages of hominoid life history 
were also associated with progressively evolving behavioural features that indicated a potential 
impact of SVA propagation on a cognitive ability of a modern human. The SVA-associated genes 
were highly cross-linked in functional networks suggesting an accumulative impact of functional 
alterations potentially caused by SVA insertions. The analysis of functional networks also pointed to 
a relevance of SVA-associated genes to a hormonal and immune modulation of behaviour and a 
crosstalk between behaviour and reproduction, that would effects inheritable propagation of SVAs 
and their accumulation in the genome. The presence of functional positive and negative feedbacks in 
the SVA-associated functional network is discussed in relation to a role of suggested waves of SVA 
and potentially other mobile elements propagation in evolution of human cognitive features. 
Conclusion 
Our analysis suggests a potential role of SVAs in evolution of human CNS and especially 
emergence of functional trends relevant to social and parental behaviour. It also supports models 
which explain in part how brain function can be modulated by both the immune and reproductive 
systems based on the gene expression patterns and gene pathways potentially altered by SVA 
insertions. 
 
 
 
 
 3 
Background  
Genetic studies have been successful at determining the changes that alter pathways 
involved in evolution. Transposable elements (TEs), despite long being thought of as ‘junk’ DNA, 
have impacted the human genome during its evolution through a variety of mechanisms causing 
structural variation such as exon disruption, generation of deletions and integration sites, 3’ or 5’ 
transduction, non-allelic homologous recombination and exonisation (Beck, et al. 2011; Goodier and 
Kazazian 2008; Muotri, et al. 2007). Furthermore, TE insertions can supply the cell with novel splice 
sites, polyadenylation signals, promoters and regulatory domains, epigenetic marks and secondary 
structures that can reorganise gene expression and build new transcription modules which could 
underpin the process of evolution (Beck, et al. 2011; Hancks, et al. 2009; Hancks and Kazazian 2010; 
Piriyapongsa, et al. 2007; Quinn and Bubb 2014; Savage, et al. 2013; Savage, et al. 2014) but also 
cause disease (Kaer and Speek 2013). Estimates have suggested over 1.5 million TEs in the human 
genome (Cordaux and Batzer 2009). Non-LTR retrotransposons constitute ~34% of the human 
genome (Beck, et al. 2011), and a subset of these elements have retained the ability to be mobilised 
within the genome generating new insertions. They have the potential to cause both “de-novo” 
germline mutations and somatic mutations which are implicated in disease progression, particularly 
in cancer and the CNS (Erwin, et al. 2014; Reilly, et al. 2013) . 
More than 10,000 TE insertions occurred in the human genome since human-chimpanzee 
divergence (Mills, et al. 2006). The large number of such TEs in the genome makes an analysis of 
their specific contribution to evolution very difficult. However, to address this contribution we have 
focused on building networks of pathways based on the proximity of genes to the integration sites of 
the hominoid-specific retrotransposons termed SINE–VNTR–Alu (SVA) elements. SVA elements are 
the youngest of the retrotransposons, and there are approximately 2700 of these elements in the 
human genome (Cordaux and Batzer 2009; Savage, et al. 2013; Wang, et al. 2005). They stand out 
from the group of human non-LTR retrotransposons due to their composite structure. Starting at the 
5′-end, a full-length SVA element is composed of a (CCCTCT) hexamer repeat region, an Alu-like 
region consisting of three antisense Alu fragments adjacent to an additional sequence of unknown 
origin, at least one variable number of tandem repeats (VNTR) region (Ostertag, et al. 2003), and a 
short interspersed element of retroviral origin (SINE-R) (Ono 1986). A poly(A) tail is positioned 
downstream of the predicted conserved polyadenylation signal AATAAA (Ostertag, et al. 2003). 
Others and we have demonstrated that these SVA domains, in addition to mobilisation, have the 
properties of transcriptional regulators of gene expression both in vivo and in vitro (Savage, et al. 
2013; Savage, et al. 2014; Zabolotneva, et al. 2012) , and that a significant number of SVAs are within 
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10kb of the major transcriptional start site of many genes (Savage, et al. 2013). Therefore, SVA 
insertions established in the hominoid lineage could be responsible for altering the transcriptome in 
a developmental, tissue specific or stimulus inducible manner. The relatively low number of SVAs 
established in the genome allows for a model to determine the gene pathways likely to be affected 
by the SVA integrations.  
SVAs are divided into subtypes A to F and F1, and their age was estimated at 13.56 million 
years (Myrs) for the oldest subtype (A) and 3.18 Myrs for the youngest subtype (F). Subtype D is by 
far the largest and encompasses 44% of all SVAs in the human genome. The most recent F1 subtype 
is the smallest group at 3%. Subtypes E, F and F1 are human-specific and correspond to the period 
since the human-chimpanzee divergence ~6 million years ago (Mills, et al. 2006). Implication of SVAs 
in evolution of hominoid lineages leaves no doubts. After the human-chimpanzee divergence, the 
SVAs continued to expand within the chimpanzee genome creating a subtype unique to 
chimpanzees called SVA PtA (Wang, et al. 2005). More recently, the family of gibbon-specific LAVA 
retrotransposons, derived from an SVA subtype A element, has been implicated in the molecular 
mechanism underpinning genome plasticity of the gibbon lineage (Carbone, et al. 2014). It was 
reported that LAVA-induced premature transcriptional termination of chromosome segregation 
genes caused the high rate of chromosomal rearrangements experienced by the gibbon lineage since 
it diverged from the other apes about 17 Myrs. An analysis of the human and chimpanzee genomes 
revealed that 46537bp have been deleted from the human genome through the processes of SVA 
insertion-mediated deletions and SVA recombination associated deletions (Lee, et al. 2012). 
In this communication, we focus on the SVAs that are part of the human genome and 
address the functional relevance of human SVA-associated genes to neurological and cognitive 
processes to demonstrate SVA insertion and subtype appearance in evolution with the correlation of 
behavioural traits. Our data also support evidence that SVA insertions can have an impact in normal 
and pathological brain functioning (Richardson, et al. 2014; Upton, et al. 2015).  
Methods 
Generation of the list of genes  associated with SVA insertions  
Genomic coordinates of all SVA loci in the human genome (Hg19 sequence) were extracted 
from the UCSC genome browser (http://genome.ucsc.edu/index.html). This included many SVA 
sequences that were fragmented in the Repeat Masker track; therefore this list was manually 
annotated to generate a list of coordinates of complete SVA sequences resulting in a total of 2676 of 
these elements encompassing the seven subtypes (Savage, et al. 2013). The coordinates of all known 
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genes and their transcripts were extracted from the UCSC genome browser, and Galaxy software 
(http://galaxyproject.org/) was used to generate coordinates of the 10-kb genomic regions flanking 
all known transcripts. Finally, the SVA loci were intersected with the three lists of genomic 
coordinates (all known genes, 10kb upstream and 10kb downstream of known genes). Duplicates 
were removed from each list individually. For functional enrichment analysis, the defined SVA 
coordinates have been used to produce a shorter list of GRch38 genes directly mapped via BIomart 
Martview service (www.biomart.org/biomart/martview/).  
Ingenuity Pathway Analysis (IPA)  
Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Inc.) was used to investigate 
biological pathways and networks as well as disease functions associated with the data set (Gietzen 
2010; IPA 2013; Jiménez-Marín, et al. 2009). The IPA database is composed of comprehensive 
information on genes and pathway ontologies. The database contains approximately 200 canonical 
pathways as well as 27 higher-order disease and function categories for ‘Core’ functional enrichment 
analysis. Right-tailed Fishers Exact statistical tests was used to calculate whether the likelihood of 
associations between a set of focus genes and a category was due to a random chance. This enabled 
evaluation of enriched functions in a pathway or higher order ontological categories and provided a 
hypergeometric distribution based network score and p-Values conveyed as the –log (Fisher’s Exact 
Test). The tool enabled production of graphical networks that illustrated mapped genes as 
shadowed objects. Un-shadowed objects were added as connectors within a network, identified by 
the software. The behavioural categories used by IPA are largely originate from experiments on 
rodents and may seem as irrelevant to human. However, parallels between mice and human 
behavioural features are widely used in neurobiology, and we try to provide these 
parallelisms/explanations of relevance to human were appropriate.  
Meta-analysis of gene expression. 
‘Genevestigator’ (Grennan 2006; Hruz, et al. 2008; Zimmermann, et al. 2005) software was 
used to perform a meta-analysis of gene expression in different tissues and areas of the human 
brain.  For each gene/tissue an average level of expression is determined via automated cross-
analysis of normalised published Agilent microarray data, filtered for statistically significant values 
and stored in the Genevestigator database. The highest and lowest detected average expression 
levels define a 100-unit scale that is used for presentation of each gene/tissue related average 
expression value. 
Results 
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Relevance of SVA-associated genes for functional categories of the neural system 
Having coordinates of SVA insertions in human genome we aimed to identify if there are any 
functional biases in the associated gene set. We have confined our functional enrichment analysis to 
those genes, which imbed an SVA insertion. Though without significant enrichment, the top (from 
2nd to 6th positions) ranked ‘Canonical pathways’ were uniformly relevant to neuronal functions 
including: ‘Synaptic Long Term Potentiation’, ‘Synaptic Long Term Depression’, ‘Axonal Guidance 
Signalling’, ‘Neuropathic Pain Signalling in Dorsal Horn Neurons’ and ‘CREB Signalling in Neurons’ 
(Table S3A).  The gene functions contributing to these canonical pathways were associated with the 
top five ‘Functions and Diseases’ categories , where ‘Guidance of axons’ and ‘Synaptic processes’ 
were significantly enriched (Table S3B).The presence of multiple top ranked neural system links was 
indicative of a potential impact of SVA insertions on neural system function at different stages of 
human cognitive and behavioural evolution. Moreover, significant enrichment of genes in a 
particular pathway or functional category could mean evolutionary functional stratification of the 
SVA insertions via positive selection of the relevant phenotypes.  The results of our analysis overall 
do not suggest that neural system was the main target of SVA attack, as the significant enrichment 
was observed only for two relevant functional categories . However, it was still interesting to see if 
we could uncover any specific  functional trends of potential SVA impact on human cognitive 
function. 
Analysis of the functional enrichment of SVA-associated genes with neuronal functions.  
To focus on potential significance of SVA insertions in function and evolution of neural 
system only genes representing relevant to CNS categories (‘Behaviour’, ‘Nervous System 
Development & Function’, ‘Neurological Diseases’ and ‘Psychological Diseases’ ) were selected 
(Tables S1 and S2) and ontologically classified by means of IPA (Table S4). The analysis of their 
biological functions showed a significant enrichment in categories of ‘Morphology of nervous 
system’ (-log(p-value)=17.9) (forebrain, and telencephalon, particularly), ’Development of central 
neural system’ (-log(p-value)=16.3) (forebrain, and telencephalon, particularly), ‘Formation of 
cellular protrusions’ (-log(p-value)=12.2) and multiple categories relevant to axon growth and 
synaptic processes (-log(p-value)>5). From all the mapped Behavioural categories, ‘Learning’ and 
‘Social behaviour’ were the most enriched (-log(p-value)>4.6) (Table S4), and ‘Nest building 
behaviour’, ‘Nursing’, ‘Sexual behaviour’, ‘Sexual receptivity of female organism’, ‘Grooming’, 
‘Emotional behaviour’, ‘Aggressive behaviour’ , ‘Vocalisation’ and ‘Walking’ significantly enriched in 
the SVA B and/or SVA D associated sets of genes. ‘Social behaviour’ was the only significantly 
enriched category attributed to the gene sets associated with the youngest, F and F1 SVAs. Many 
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categories across the sets were mapped by one or two genes (Table S5) and were not considered as 
significant. All the defined behavioural categories were presented against the timeline of occurrence 
of insertions of the different SVA subtypes in the human genome as shown on Figure 1. 
 
Fig.1. Behavioural categories attributed to genes associated with SVAs at different time 
points during evolution. 
Our results suggest a functional relevance of SVA-mediated modification of individual genes, 
which could be attributed to the evolutionary behavioural changes.  Some categories used by IPA ( 
such as nest building) and consequently, functional meaning of potential modification of gene 
activity due to SVA insertion may be not obvious at first glance. Nevertheless, without going through 
all the genes in this list, we have outlined below using few examples how SVAs could be involved in 
evolution. It can be seen that the gene ATG7 (Autophagy related 7 homolog), that contains an SVA 
F1 insertion, is associated in the database with the ‘Walking’ functional category (Table S5,), 
supporting the hypothesis that younger SVA subtypes could affect the particular locomotor patterns 
of pre-modern human favouring emergence of the new characteristics. The walking-category-
associated group of genes (AGTPBP1 (ATP/GTP binding protein 1), CACNB4 (Calcium channel, 
voltage-dependent, B4 subunit), FXN (Frataxin), SCN8A (Sodium channel, voltage gated, type VIII 
alpha subunit) also contain SVA D insertions (Table S5) which potentially reflects their involvement in 
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development of erect walking, characteristic of a chimpanzee-hominid phylogenetic branch (Figure 
1). Conversely, the functions of climbing activity-associated genes KCNJ6 (Potassium inwardly-
rectifying channel, J6) and HTT (Huntingtin) could be modulated or suppressed by SVA A and B 
insertions very early in hominoid evolution (Table S5). Alteration of the functionality of these genes 
overall could have had a strong impact on changing from climbing to the walking moving mode. 
Mother preference associated gene OMP (Olfactory marker protein) was present in the SVA F 
subtype group as were the nursing and feeding associated genes ACOT11 (Acyl-CoA thioesterase) 
and MKL1 (Megakaryoblastic leukaemia (translocation) (Table S5). These latter genes may be 
proposed for a role in the progression of maternal behaviour and neotenic features in human 
evolution (Figure 1). Behavioural characteristics encoded by genes containing younger SVA elements 
are generally of a more executive nature (Table S5): for instance, CREB1 (cAMP responsive element 
binding protein 1), associated with an SVA E insertion, is involved in both vertical and spatial learning 
and place preference, while PSEN1 (Presenilin-1) is associated with an SVA F element and plays a 
role in social order recognition, memory and social behaviour. 
Several genes in our list are associated with multiple categories, e.g. the genes HTT (SVA B 
subtype group) or BRCA1 (Breast cancer type 1 susceptibility protein) (SVA F subtype group) could 
have been especially significant at particular evolutionary stages whilst having largely pleiotropic 
effects (Figure 2). Related functional networks enriched in genes with SVA insertions and belonging 
to neuronal/behavioural categories (Figure 2A, B) showed that genes harbouring different SVA 
subtypes interact and the changes in gene expression caused by SVA insertions may be synergistic 
with an accumulative or compensatory impact on particular phenotypes. Interestingly, 13 functions 
have been found to be associated with multiple different (at least 3) SVA subtypes (Table 1), from 
which six genes occurred to be connected in one functional network (Figure 3). The network 
connectivity of this gene set (Figure 3) demonstrates direct links from the genes BCYRN1 and MAP4 
to X-chromosome fragility susceptibility gene FMR1, and  functional association with the PGR 
(Progesterone receptor) and ZNF640 (Zink finger 640) via mir-548 family of regulatory RNAs. 
Interestingly, 24 additional genes attributed to X-linked mental retardation were present in our SVA-
associated data set (Table 2). Categories relevant to X-linked mental retardation were significantly 
enriched in several gene sets (Figure 4); it was also shown for ‘Seizure’, ‘Movement’ and ‘Mood ‘, 
Alzheimer, Parkinson CNS disorders and Schizophrenia  in association with different SVA types 
(Figure 4). 
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 Table 1.  Genes associated with 3 and more SVA insertions. The presence of a particular SVA type in 
a gene or in 10kB gene proximity is indicated by ‘+’. 
Gene 
Function                                                                        
SVA: A B C D E F F1 
BCYRN1 Brain cytoplasmic RNA 1  +  +   +   +  
DLEC1 Deleted in lung and esophageal cancer 1   +  +     + 
EIF4G3 Eukaryotic translation initiation factor 4 gamma, 3     +  +  +  
TAF1 TAF1 RNA polymerase II, (TBP)-associated factor   +    +    
SIMC1 SUMO-interacting motifs containing 1     +   +  
CCDC109B Coiled-coil domain containing 109B  +  +   +    
WDR70 WD repeat domain 70  +   +  +    
DST Dystonin   +   +  +   
UBR1 
Ubiquitin protein ligase E3 component n-recognin 
1   +   +  +   
KDM4C Lysine (K)-specific demethylase 4C    +  +   +  
MAP4 Microtubule-associated protein 4    +  +   +  
mir-548 MicroRNA 548c     +  +  +  
PTPN9 Protein tyrosine phosphatase, non-receptor type 9    +  +    + 
 
 Fig.2. Functional networks reconstructed from SVA-associated genes classified in neuronal 
and behavioural categories.  The initial networks reconstructed by IPA from uploaded dataset 
(coloured blocks) have been refined by deletion of automatically added low-connected nodes. Fx- 
labels correspond to gene-attributed functions and diseases. Solid lines reflect experimentally 
validated functional interactions, and dashed lines indicate protein binding. A) A network of genes 
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associated with HTT (Huntingtin), who’s connections are highlighted in blue. The colour intensities of 
blocks correspond to different SVA-subtypes increasing in the order: B, C, D, F1. Presence of multiple 
SVA subtypes is indicated in associated textboxes. The majority of interacting genes has intragenic 
SVA insertions; presence of upstream or downstream insertions is indicated by blue lettering. 
 
B) A top-ranked network with assigned relevance to DNA recombination and repair 
associated with BRCA1 (Breast cancer associated 1), who’s connections are highlighted in blue. The 
colour intensities of blocks correspond to types of intragenic SVA insertions increasing in the order: 
B, D, F. Blue lettering indicates the genes associated with neuronal and behavioural categories. 
ACOT11-Acyl-CoA thioesterase 11, CDK5RAP2-CDK5 regulatory subunit associated protein 2, DIXDC1- 
DIX domain containing 1, E2F-Elongation factor 2, ESR1-Estrogen receptor1, FANCA-Fanconi anemia  
protein A, FANCD2-Fanconi anemia protein D2, HdaC-Histone deacetylase, MSH2-MutS homolog 2, 
NPM1-Nucleophosmin, POLA1-Polymerase (DNA directed), alpha 1, catalytic subunit, RBL1- 
Retinoblastoma-like 1, VPS35-Vacuolar protein sorting 35 homolog . 
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Fig.3. A network reconstructed from genes (red objects) with three and more different 
intragenic SVA insertions. Associated genes containing less than three SVA insertions are presented 
in pink and linking genes- in white . X-chromosome fragility gene FMR1 and the KRAB-family ZNF680 
are highlighted in blue and green, respectively. Linked text labels (connected by orange lines) 
correspond to gene-attributed functions and diseases. Solid lines reflect experimentally validated 
functional interactions and dashed lines correspond to protein binding. Shortest paths from SVA-
associated genes to FMR1 are highlighted in blue. BCYRN1 -Brain cytoplasmic RNA 1, lncRNA,TAF1 -
TATA box binding protein, DLEC1-Deleted in lung and oesophageal cancer 1, EIF4G3-Eukaryotic 
translation initiation factor 4 gamma, Map4-Microtubule-associated protein, mir-548 – micro RNA.  
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Fiig.4. Link of genes associated with SVA insertions to neural and psychiatric diseases.  
Colours correspond to particular types of SVA (columns) in genes from certain disease categories 
(rows). A significant enrichment (p-value<0.05) of the neuronal/behavioural gene dataset in the a 
category is highlighted in blue, light blue corresponds to a higher ( p<0.01) significance of the 
functional enrichment. 
Meta-analysis of anatomical relevance of SVA-associated behavioural gene expression.  
The forebrain and hidbrain were confirmed to be the sites of high expression of the majority 
of the genes attributed to behavioural phenotypes. High expression levels of the majority of genes 
associated with all 7 SVA subtypes were also found outside of the CNS. Potential positive selection of 
SVA-associated genes could be attributed among other factors to their direct effect on an organism’s 
reproduction. Nearly all genes associated with members of the SVA A and B subtypes were highly 
expressed in placental chorion. All genes were expressed in testis at above average levels. A number 
of the behavioural SVA-associated genes exhibited in oocytes the highest expression levels (TIMD4, 
OXT, KALRN, MKL1, ATG7, cyp7B1) with noticed enrichment of such genes in SVA F1 and SVA F 
associated. Some genes whose expression results in a validated, strong ‘neural’ phenotype, such as 
GABBR2 (SVA A) and CREB1 (SVA E), are also highly expressed in oocytes.  Interestingly, the germline 
cells are reported to be sites of increased mobilisation of endogenous retrotransposons in general 
(Levin and Moran 2011), and attribution of SVAs to genes expressed in these tissue might therefore 
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be relevant to the SVA inheritable propagation. Analysis of attribution of the gene set with neuronal 
and behavioural functions in phenotypic reproductive categories (IPA analysis) also highlighted their 
link to: spermatogenesis (sperm motility (ADCY10), atrophy of testis and seminiferous tubules (HTT), 
in particular), infertility in both genders (STAR, ABCA1, MKKS, NPEPPS), maturation (LFNG) and 
fertilisation (CLIC4) of oocytes. Several genes, such as CYp19A1, ESR1, ABL2, CREB1, NPEPPS and 
SHANK1 also have an association in the IPA knowledgebase with behavioural aspects of 
reproduction: sexual receptivity of female organism, mating behaviour, intromission, mounting and 
pup retrieval.  
High expression levels of the SVA-associated genes, in particular of those with the youngest 
SVA subtypes (APL2, OMP, PSEN1, and ATG7, for instance) and few with older subtipes (Hpp) were 
also observed in the immune system. This was of interest given the current attention to the 
immune–CNS axis and how interactions between the immune system and CNS may not only regulate 
normal physiology but are also be associated with mental health issues.  HTT was the only gene of 
the gene group associated with SVA A or SVA B elements that was strongly expressed in cells of the 
immune system.  
Discussion 
Retrotransposons have been suggested to be major drivers of genome evolution, both 
through structural variations such as insertional mutagenesis and modulation of the transcriptome. 
For the latter, retrotransposons are a source of regulatory elements providing promoters (sense and 
antisense), binding sites for transcription factors and polyadenylation signals that could affect gene 
expression (Rebollo, et al. 2012). SVAs can also induce an alternative splicing and exon skipping 
which can result in the generation of alternative transcripts of a gene as documented by disease 
causing insertions (Hancks and Kazazian 2012; Kaer and Speek 2013; Nakamura, et al. 2015). 
Furthermore, the SVA encoded SINE-R module contains human endogenous retrovirus HERV-K10 
LTR sequences that are suggestively involved in the regulation of gene expression (Fairbanks, et al. 
2012; Xing, et al. 2006); and at least in case of SVA D, they indeed supported reporter gene 
expression in vivo and in vitro (Savage, et al. 2013; Savage, et al. 2014). Thus, SVA insertions may 
generate new interactions between what would otherwise be distinct pathways (Quinn and Bubb 
2014).   
SVAs share many DNA sequence homologies across subtypes and, as a result, could respond to 
related or similar stimuli giving a concerted gene response to the environment or challenge. We 
have therefore focused on pathways involved in CNS function and predicted to be modulated by 
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human genes encompassing or adjacent to SVA insertions. Our data has established that more 
primitive behavioural characteristics are prominent in the genes associated with the older SVA 
subtypes A, B and C. Results revealed a striking correlation between the timing of SVA insertions and 
functional significance of these associated genes at particular stages of hominoid evolution. For 
example, genes associated with SVA A and B insertions (which expanded contemporary to the 
divergence of the orang-utan and the great apes (Wang, et al. 2005)), influence climbing ability. In 
contrast, genes containing SVA F insertions (which expanded after the human and chimpanzee 
divergence(Wang, et al. 2005)) were found to affect more advanced motor skills such as walking 
(Figure 1).  Similarly, the analysis revealed that complex behavioural characteristics (such as 
discriminatory learning, sexual, social and especially maternity care) correlated with the more recent 
SVA insertions (Figure 1). Meta-analysis of gene expression data revealed that genes associated with 
older SVA insertions are more strongly expressed in structures of the brain that evolved earlier, such 
as the pyramidal regions. It is also noteworthy that SVA F and F1 insertions   were strongly 
associated with genes involved in the immune system which is considered a major modulator of CNS 
function, and in neuropsychiatric disorders such as autism, schizophrenia and depression [TC 
Network (2015)]. Interestingly, increased brain size in mammals was also shown to be also 
associated with size variations in immune system-involved gene families (Castillo-Morales, et al. 
2014). Late age-related phenotypes of SVA insertions could also play a role in reduction of the 
reproductive age and general neotenisation of the human population. 
 SVA insertions could also have an influence on human gender-specific brain function via sensing 
hormonal backgrounds. The BRCA1 gene (Figure 2B), which is associated with an SVA F insertion, 
was shown to be in a functional cross talk with the oestrogen receptor ESR1 (Gorrini, et al. 2014; 
Kang, et al. 2012). It is also known to have a strong role in a control of brain size (Pao, et al. 2014; 
Pulvers and Huttner 2009), especially in regions responsible for learning, memory, muscle control 
and balance. Interestingly, progesterone-dependent transcription factor, PGR, which binding sites 
were shown to be enriched in ancient mammalian TEs (Lynch, et al. 2015), was also associated with 
a network of genes with multiple intragenic SVA insertions (Figure 3).  
There is an intriguing correlation in expression of many SVA-associated genes in brain and testis, and 
a very strong expression of some of these genes with behavioural phenotypes in oocytes. It may be 
relevant to regulation of the genes via putative alternative promoters (PAPs)(Kimura, et al. 2006) 
especially enriched in those tissues and potentially associated with SVA elements.  Moderate 
expression of the majority of behavioural- SVA-associated genes in male germ cells (in contrast to 
only few, though strongly, expressed in oocyte) could make this cell type a particular source of 
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mobilized SVAs and also a place for their inheritable trans-mobilisation. It would be supported by a 
strong expression in this niche (as well as in an early embryo) of retroviruses and L1 
retrotransposons as the required providers of the reverse transcriptase (Han, et al. 2004; Levin and 
Moran 2011; Zamudio and Bourc'his 2010).  The observed correlation means that certain 
behavioural trends caused by SVA insertions could be genetically linked to a higher rate of an 
inheritable SVA trans-mobilisation. Being subjected to positive or negative selection at particular 
stages of hominoid evolution those behavioural trends therefore could be associated with waves of 
inheritable SVA propagation in the genome. Such activated trans-mobilisation of SVAs in its turn 
could lead to increased genome instability and chromosome fragility affecting also the rates of 
somatically-driven CNS disorders. It would finally suppress a positive selection of genotypes 
favouring such inheritable trends. The presence of the hypothesised feedbacks is supported by a 
number of our observations. DNA recombination and repair were amongst the top categories in 
functional groupings enrichment analysis of all SVA associated functions (Figure 2B, Table S3), and X-
fragility-relevant genes populated the list of behavioural SVA-associated ones (Figure 3, Table 2), 
which may reflect on the mechanisms of how SVAs can affect their propagating properties. This is 
also consistent with reported genome instability caused by mobile elements (Kim and Hahn 2011). 
Genes associated with both neuronal and reproductive phenotypes as well as with SVA trans-
mobilisation properties (for instance, BRCA1 or the KRAB proteins (ZNF680 & ZNF91/93) (Jacobs, et 
al. 2014; Thomas and Schneider 2011) could be in the first line of the SVA-driven evolutionary 
changes in the hominoid lineage (Figure 4). The network reconstructed from those genes, that are 
especially enriched in SVA insertions (Figure 3), highlights interacting negative (KRABs, miRNAS) and 
positive (BCYRN1, miRNA) pathways, which could be extended to gene silencing and RNA 
interference by the piwiRNA pathway (Figure 5) (Bao and Yan 2012; Kapusta, et al. 2013; Zamudio 
and Bourc'his 2010) in regulation of SVA propagation. 
SVAs are present in genes, which have been linked to different psychiatric conditions ranging 
from intellectual disability (mental retardation) to epilepsy and bipolar disorder (Figure 4). Human 
specific SVA insertions are known to be polymorphic for their presence or absence (Bennett, et al. 
2004), and with continued retrotransposition there are likely to be many private insertions within a 
population. The polymorphic nature of SVA elements is also exhibited in terms of the number of 
repeats within their central VNTR region and hexamer domains (Savage, et al. 2013). VNTRs, as 
individual elements, are associated with the differential expression of genes involved in human 
behaviour such as those found with the genes encoding monoamine oxidase A, serotonin and 
dopamine transporters (Hill, et al. 2013; Lovejoy, et al. 2003; Michelhaugh, et al. 2001) and 
constitute risk factors for a variety of behavioural disorders and psychiatric diseases dependent on 
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the copy number of the repeat present(Savage, et al. 2013)(Savage, et al. 2013)( (Ali, et al. 2010; 
Breen, et al. 2008; Galindo, et al. 2011; Hill, et al. 2013; Klenova, et al. 2004; Paredes, et al. 2012; 
Pickles, et al. 2013; Roberts, et al. 2007; Vasiliou, et al. 2012). Furthermore, the VNTR domain plays a 
major role in the trans-mobilisation of SVA elements by the L1-encoded protein machinery (Han, et 
al. 2004; Hancks and Kazazian 2010; Raiz, et al. 2012). 
 
Fig.5. Schematic presentation of regulatory and evolutionary functional interactions involved 
in SVA trans-mobilisation. Bold arrows correspond to inhibitory (blue) or activatory (red) effects. 
Functions targeted by SVA insertions are highlighted in purple. RT-reverse transcriptase, Rb-
Retinoblastoma protein, HDAC-histone deacetylase, piRNA-piwiRNA, APOBEC-Apolipoprotein B 
mRNA editing enzyme, catalytic polypeptide-like. Regulators of L1 expression are not shown. 
Conclusions  
Our systems analysis suggests an impact of SVA retrotransposition on evolution and 
performance of human cognitive functions. It has revealed that insertions of members of the older 
SVA subtypes A-C occurred in genes involved in more primitive characteristics whereas younger SVA 
D-F1 insertions were present in genes linked to more sophisticated human-specific traits. SVA 
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insertions were also found to be enriched in genes involved in networks and pathways relevant to 
neuronal function and CNS disorders. The presence of SVAs in multiple genes within a network may 
allow for a concerted response to an environmental stimulus modulated by factors targeting SVA 
regulatory sequences. Potential positive feedbacks in functional interactions of genes with inserted 
SVAS would have a larger impact on phenotype compared to if only a single gene within a pathway 
contained an SVA insertion. Negative feedbacks in these functional networks and co-evolution of 
factors that limit SVA propagation, from the other side, would play a genome-stabilising role. Taking 
in consideration genetic polymorphisms in human population associated with SVA insertions and 
documented somatic mobility of the youngest SVAs in human  brain and germ tissues, one can 
suggest that SVAs also have a strong modulatory impact on recent human behavioural trends and  
human susceptibilities to psychiatric disorders. 
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Supplementary materials: 
Table 1. Genes associated with SVAs classified to 4 categories relevant to neural system 
function. 
SVA_A SVA_B SVA_C SVA_D SVA_E SVA_F SVA_F1 
BEHAVIOUR 
GABBR2
KCNJ6, 
PLCB4 
CLCN3, 
HDAC4, 
HTT,MAPK1, 
RCAM, 
NRXN1, OXT, 
SEC24D, 
TACR3, 
TIMD4, UBR1, 
USF1 
ABCA1, 
ABHD12, 
ATF2, 
FGF12, 
LRRK2, 
MKKS, 
NPEPPS, 
SLC16A2 
ABL2, AGTPBP1, ATP7A, 
ATP8A2, CACNB4, CNTNAP2, 
CYP19A1, ESR1, F2RL1, FTO, 
FXN, GABRA2, GABRG3, 
GFRA2, GNAQ, GPHN, IL1RN, 
LEPR, LRPAP1, MOS, 
MTOR,NFATC3, NIPBL, NRXN1, 
OCLN, PARK7, PBX3, PRKG1, 
SCN8A, SHANK2, SYTL4,TRPV1, 
UBR1, VAMP7, VEZT 
CREB1, 
OPHN1, 
UBR1 
APLP2, 
KALRN, 
LEF1, 
MYH10, 
OMP, 
PARK2, 
PDE11A, 
PSEN1 
ACOT11, 
ATG7, 
CYP7B1, 
MKL1 
NERVOUS SYSTEM DEVELOPMENT & FUNCTION 
ADCY10
AKAP9, 
CASP6, 
GABBR2, 
KCNJ6, 
PHB, 
PLCB4, 
SMO, 
TRA, 
ULK4, 
UNC13B 
ARHGAP5, 
CLCN3, 
CNTN4, 
DCLK1, DST, 
FBXL20, 
GRID1, 
HDAC2, 
HDAC4, HTT, 
MAPK1, 
MYO5A, 
NCOR1, 
NR1H2, 
NRCAM, 
NRXN1, OXT, 
ALPL, 
APBB2, 
ATF2, 
HEY2, 
HYOU1, 
LAMA2, 
LRRK2, 
MKKS, 
PARG, 
PTPN9, 
RORA, 
SIL1, STAR 
ABL2, ADAM19, AGTPBP1, AHI1, 
ALOX5, ANK2, ARHGAP35, 
ASPA, ATP7A, ATP8A2, ATRX, 
ATXN2, BRAF, C2CD3, CACNB4, 
CAMK1D, CNTNAP2, CRB1, 
CYP19A1, DDIT3, DIXDC1, 
EIF2B3, EIF4G3, ELMO1, 
ERBB2IP, ESR1, F2RL1, FAIM2, 
FER, FGD4, FTO, FXN, GFRA2, 
GNAQ, GPHN, IL1RAPL1, IL1RN, 
JARID2, KIF15, LEPR, LILRB3, 
LPAR4, LRP4, LRPAP1, MOS, 
MTOR, MYH9, NCOR1, NFATC3, 
NIPBL, NRXN1, NRXN2, OCLN, 
ADIPOQ, 
ANXA2, 
ATP2C1, 
CASP8, 
CLIC4, 
CREB1, 
DST, 
LFNG, 
OPHN1, 
UBR1, 
VAV2 
APAF1, 
APLP2, 
BRCA1, 
CLIC4, 
EIF2B4, 
ERBB3, 
FSTL1, 
KALRN, 
LEF1, 
LRP2, 
LRRC4C, 
MYH10, 
NPM1, 
OMP, 
ATG7, 
CDK5RAP2, 
CYP7B1, 
HTR1E, 
PTPN9, 
SV2C 
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PARD3, 
PDS5B, 
PRPH2, 
RPGRIP1L, 
SMAD2, 
TACR3, 
TRPM6, 
UBR1, UBR2, 
UTRN 
PARK7, PBX3, PCMT1, PDGFRA, 
PDS5B, PEX5, POR, PRKG1, 
PTPN9, RBL1, RGS11, 
RPGRIP1L, SCN8A, SHANK2, 
SIL1, SLC17A5, SNTB2, SPTBN1, 
SYNE2, SYTL4, TACC2, TENM4, 
TRPV1, TRPV3, UBE4B, UBR1, 
ULK1, ULK4, UTRN, VAMP7, 
VEZT, YWHAE 
PARK2, 
PDE11A, 
PPARD, 
PSEN1, 
RBL1, 
ROBO2. 
TENM4, 
ZEB1 
NEUROLOGICAL DISEASE 
AARS2, 
ARL13B, 
BBS9, 
CASP6, 
CLN6, 
DYX1C1, 
FAF1, 
GABBR2, 
KCNJ6, 
MKS1, 
PHB, 
PLCB4, 
REEP1, 
RTTN, 
SMO, 
TAF1, 
TRA, 
ULK4, 
UNC13B 
ACSL4, 
CACNA2D4, 
CCM2, 
CLCN3, DST, 
FAF1, GRID1, 
HDAC4, 
HDAC8, HLA-
DRB1, HTT, 
IGBP1, IGBP1, 
NR1H2, 
NRCAM, 
NRXN1, OXT, 
PARD3, 
PARP1, 
PDS5B, 
PRPH2, 
PTPRD, 
RPGRIP1L, 
SMAD2, 
TACR3, 
TRPM6, 
UBR1, YARS, 
ZDHHC15 
ABCA1, 
ABHD12, 
APBB2, 
ARNT, 
ATF2, 
CFLAR, 
DNAJC1, 
DYSF, 
FGF12, 
HYOU1, 
KDM6A, 
LAMA2, 
LOC440040,
LPIN1, 
LRRK2, 
MFN2, 
MKKS, 
PARG, 
PIGL, 
PNKD, 
PTPN9, 
RAB7A, 
RORA, 
SIL1, 
SLC16A2, 
SLC25A12, 
STAR, 
TFAP2B, 
VAMP1, 
WDR62 
ADAM19, ADORA3, AHI1, AIP, 
ALOX5, ANKRD11, ARHGAP35, 
ASPA, ATP7A, ATRX, ATXN2,, 
BBS5, BRAF, BRWD3, C9, 
CACNB4, CAMTA1, CASK, CFB, 
CNTNAP2, CPA6, CRB1, 
CYP19A1, DDIT3, EIF2B3, 
ELMO1, ESR1, F2RL1, FGD4, 
FUS, FXN, GABRA, GABRG3, 
GFRA2, GLRA3, GNAQ,GOLPH3, 
GPR98, IL1RAPL1, IL1RN, LEPR, 
LRP4, LRPAP1, MSH2, MTOR, 
MYH9, NRXN1, OCLN, OTOGL, 
PARK7, PCMT1, PDE4D 
PDGFRA, PDS5B, PEX5, 
PHF8PIGV, PNPT1POR, PTPN9, 
PUS1, RAB7A, RBL1, RMND1, 
RPGRIP1L, SCN8A, SIL1, 
SNTB2, SPRN, SPTBN1, SYTL4, 
TAF1, TAOK1, TENM4, TRIOBP, 
TRPV1, UBE4B, UBR1, ULK4, 
VAMP7, VPS35, XK, YWHAE, 
ZDHHC9 
ADIPOQ, 
ANXA2, 
ATP2C1, 
BRAT1, 
CASP8, 
CREB1, 
DST, 
HMBOX1,
HUWE1, 
MYO1B, 
NBAS, 
OPHN1, 
PDE9A, 
PDXDC2P, 
RNF135, 
SNX2, 
UBR1, 
VAV2 
ALDH7A1, 
APAF1, 
APLP2, 
BRCA1, 
CECR2, 
CTSS, 
EIF2B4, 
ERBB3, 
IFT140, 
KDM6A, 
LRP2, 
MS4A1, 
NEU1, 
ORC6, 
PARK2, 
PCSK5, 
PPARD, 
PSEN1, 
RANBP2, 
SERAC1, 
SLC30A10, 
SPTLC1, 
TMC1, 
VAPB, 
VPS35 
ACOT11, 
ATG7, 
CDK5, 
RAP2, 
CYP7B1, 
POLA1, 
PTPN9, 
RAD54L, 
SLMAP, 
SV2C 
PSYCHOLOGICAL DISEASE 
GABBR2
ULK4 
CACNA2D4, 
HLA-DRB1, 
HTT, NRXN1, 
OXT, PTPRD 
ABCA1, 
APBB2, 
ARNT, 
CFLAR, 
DNAJC1, 
DYSF, 
FGF12, 
LOC440040
LRRK2, 
MFN2, 
PNKD, 
STAR, 
VAMP1 
ADORA3, ALOX5, ANKRD11, 
ASPA, BRAF, C9, CACNB4, CFB, 
CRB1, CYP19A1, DDIT3, EIF2B3, 
ELMO1, ESR1, GABRA2, 
GABRG3, GOLPH3, IL1RN, 
LRP4, LRPAP1, MSH2, MTOR, 
MYH9, NRXN1, PARK7, PCMT1, 
PDE4D, PEX5, SCN8A,SYTL4, 
TENM4, TRPV3, UBE4B, 
UBR1,ULK4, VAMP7,VPS35 
ANXA2, 
CASP8, 
CREB1, 
HUWE1, 
MYO1B, 
PDE9A, 
UBR1 
APLP2, 
BRCA1, 
CTSS, 
PARK2, 
PSEN1, 
SLC30A10
SPTLC1, 
VPS35 
ACOT11, 
RAD54L, 
SLMAP 
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Table S2. SVA-associated genes with neuronal function and their SVA insertion locations 
(Upstr.-within 10kb upstream, Downst.-within 10Kb downstream a gene). 
    Gene SVA-insertion location         
Symbol Entrez Gene Name Within Upstr. Downstr. 
Protein 
location 
Molecular 
function 
Entrez 
Gene ID 
for 
Human 
Entrez 
Gene ID 
for 
Mouse 
VAMP1 
Vesicle-Associated 
Membrane Protein 1 
(Synaptobrevin 1) -- VAMP1 -- 
Vesicle 
membrane other 6843 22317 
FUS 
Fus fused in sarcoma RNA 
binding protein -- FUS -- Cytoplasm other 2521 233908 
AARS2 
alanyl-tRNA synthetase 2, 
mitochondrial -- AARS2 -- Cytoplasm enzyme 57505 224805 
ABCA1 
ATP-binding cassette, sub-
family A (ABC1), member 1 ABCA1 -- -- 
Plasma 
Membrane transporter 19 11303 
ABHD12 
abhydrolase domain 
containing 12 ABHD12 -- -- Other enzyme 26090 76192 
ABL2 
ABL proto-oncogene 2, 
non-receptor tyrosine 
kinase ABL2 -- -- Cytoplasm kinase 27 11352 
ACKR2 
atypical chemokine 
receptor 2 -- -- CCBP2 
Plasma 
Membrane 
G-protein 
coupled 
receptor 1238 59289 
ACOT11 acyl-CoA thioesterase 11 ACOT11 -- -- Cytoplasm enzyme 26027 329910 
ACSL4 
acyl-CoA synthetase long-
chain family member 4 ACSL4 -- -- Cytoplasm enzyme 2182 50790 
ADAM19 
ADAM metallopeptidase 
domain 19 ADAM19 -- -- 
Plasma 
Membrane peptidase 8728 11492 
ADCY10 
adenylate cyclase 10 
(soluble) -- -- 
ADCY1
0 Cytoplasm enzyme 55811 271639 
ADGRV1 
adhesion G protein-
coupled receptor V1 GPR98 -- -- 
Plasma 
Membrane 
G-protein 
coupled 
receptor 84059 110789 
ADIPOQ 
adiponectin, C1Q and 
collagen domain 
containing -- -- 
ADIPO
Q 
Extracellula
r Space other 9370 11450 
ADORA3 Adenosine A3 Receptor ADORA3 -- -- 
Plasma 
Membrane 
G-protein 
coupled 
receptor 121933 562 
AGTPBP1 ATP/GTP binding protein 1 AGTPBP1 -- -- Nucleus peptidase 23287 67269 
AHI1 
Abelson helper integration 
site 1 AHI1 -- -- Cytoplasm other 54806 52906 
AIMP1 
aminoacyl tRNA 
synthetase complex-
interacting multifunctional 
protein 1 AIMP1 -- -- 
Extracellula
r Space cytokine 9255 13722 
AIP 
aryl hydrocarbon receptor 
interacting protein -- AIP -- Nucleus 
transcriptio
n regulator 9049 11632 
AKAP9 
A kinase (PRKA) anchor 
protein 9 AKAP9 -- -- Other other 10142 100986 
ALDH7A1 
aldehyde dehydrogenase 7 
family, member A1 ALDH7A1 -- -- Cytoplasm enzyme 501 110695 
ALOX5 
arachidonate 5-
lipoxygenase ALOX5 -- -- Cytoplasm enzyme 240 11689 
ALPL 
alkaline phosphatase, 
liver/bone/kidney -- ALPL -- 
Plasma 
Membrane 
phosphatas
e 249 11647 
ANK2 ankyrin 2, neuronal ANK2 -- -- 
Plasma 
Membrane other 287 109676 
ANKRD11 ankyrin repeat domain 11 ANKRD11 -- -- Nucleus other 29123 77087 
ANXA2 annexin A2 ANXA2 -- -- 
Plasma 
Membrane other 302 12306 
APAF1 
apoptotic peptidase 
activating factor 1 APAF1 -- -- Cytoplasm other 317 11783 
APBB2 
amyloid beta (A4) 
precursor protein-binding, APBB2 -- -- Cytoplasm other 323 11787 
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family B, member 2 
APLP2 
amyloid beta (A4) 
precursor-like protein 2 APLP2 -- -- Cytoplasm other 334 11804 
ARHGAP5 
Rho GTPase activating 
protein 5 
ARHGAP
5 -- -- Cytoplasm enzyme 394 11855 
ARHGAP3
5 
Rho GTPase activating 
protein 35 -- -- 
ARHGA
P35 Nucleus 
transcriptio
n regulator 2909 232906 
ARL13B 
ADP-ribosylation factor-
like 13B ARL13B -- -- 
Extracellula
r Space other 200894 68146 
ARNT 
aryl hydrocarbon receptor 
nuclear translocator ARNT -- -- Nucleus 
transcriptio
n regulator 405 11863 
ASPA aspartoacylase -- ASPA -- Cytoplasm enzyme 443 11484 
ATF2 
activating transcription 
factor 2 ATF2 -- ATF2 Nucleus 
transcriptio
n regulator 1386 11909 
ATG7 autophagy related 7 ATG7 -- -- Cytoplasm enzyme 10533 74244 
ATP2C1 
ATPase, Ca++ transporting, 
type 2C, member 1 ATP2C1 -- -- Cytoplasm transporter 27032 235574 
ATP7A 
ATPase, Cu++ transporting, 
alpha polypeptide ATP7A -- -- 
Plasma 
Membrane transporter 538 11977 
ATP8A2 
ATPase, 
aminophospholipid 
transporter, class I, type 
8A, member 2 ATP8A2 -- -- 
Plasma 
Membrane transporter 51761 50769 
ATRX 
alpha thalassemia/mental 
retardation syndrome X-
linked ATRX -- -- Nucleus 
transcriptio
n regulator 546 22589 
ATXN2 ataxin 2 ATXN2 -- ATXN2 Nucleus other 6311 20239 
BBS5 Bardet-Biedl syndrome 5 BBS5 -- -- Cytoplasm other 129880 72569 
BBS9 Bardet-Biedl syndrome 9 BBS9 -- -- 
Extracellula
r Space other 27241 319845 
BRAF 
B-Raf proto-oncogene, 
serine/threonine kinase BRAF -- -- Cytoplasm enzyme 673 109880 
BRAT1 
BRCA1-associated ATM 
activator 1 -- -- BRAT1 Nucleus other 221927 231841 
BRCA1 
breast cancer 1, early 
onset BRCA1 -- -- Nucleus 
transcriptio
n regulator 672 12189 
BRWD3 
bromodomain and WD 
repeat domain containing 
3 BRWD3 -- -- Other other 254065 382236 
C9 complement component 9 C9 -- -- 
Extracellula
r Space other 735 12279 
C2CD3 
C2 calcium-dependent 
domain containing 3 C2CD3 -- -- Cytoplasm other 26005 277939 
CACNA2D
4 
calcium channel, voltage-
dependent, alpha 2/delta 
subunit 4 
CACNA2
D4 
CACNA2
D4 -- 
Plasma 
Membrane ion channel 93589 466912 
CACNB4 
calcium channel, voltage-
dependent, beta 4 subunit CACNB4 -- -- 
Plasma 
Membrane ion channel 785 12298 
CAMK1D 
calcium/calmodulin-
dependent protein kinase 
ID CAMK1D -- -- Cytoplasm kinase 57118 227541 
CAMTA1 
calmodulin binding 
transcription activator 1 CAMTA1 -- -- Other other 23261 100072 
CASK 
calcium/calmodulin-
dependent serine protein 
kinase (MAGUK family) CASK -- -- 
Plasma 
Membrane kinase 8573 12361 
CASP6 
caspase 6, apoptosis-
related cysteine peptidase -- -- CASP6 Cytoplasm peptidase 839 12368 
CASP8 
caspase 8, apoptosis-
related cysteine peptidase CASP8 -- CASP8 Nucleus peptidase 841 12370 
CCM2 
cerebral cavernous 
malformation 2 -- CCM2 -- Cytoplasm other 83605 216527 
CDK5RAP
2 
CDK5 regulatory subunit 
associated protein 2 
CDK5RAP
2 -- -- Cytoplasm other 55755 214444 
CECR2 
cat eye syndrome 
chromosome region, 
candidate 2 -- -- CECR2 Nucleus other 27443 330409 
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CFB complement factor B CFB -- -- 
Extracellula
r Space peptidase 629 14962 
CFLAR 
CASP8 and FADD-like 
apoptosis regulator CFLAR -- CFLAR Cytoplasm other 8837 12633 
CLCN3 
chloride channel, voltage-
sensitive 3 CLCN3 -- -- 
Plasma 
Membrane ion channel 1182 12725 
CLIC4 
chloride intracellular 
channel 4 CLIC4 CLIC4 -- 
Plasma 
Membrane ion channel 25932 29876 
CLN6 
ceroid-lipofuscinosis, 
neuronal 6, late infantile, 
variant CLN6 -- -- Cytoplasm other 54982 76524 
CNTN4 contactin 4 CNTN4 -- -- 
Plasma 
Membrane enzyme 152330 269784 
CNTNAP2 
contactin associated 
protein-like 2 CNTNAP2 -- -- 
Plasma 
Membrane other 26047 66797 
CPA6 carboxypeptidase A6 CPA6 -- -- 
Extracellula
r Space peptidase 57094 329093 
CRB1 
crumbs family member 1, 
photoreceptor 
morphogenesis associated CRB1 -- -- 
Plasma 
Membrane other 23418 170788 
CREB1 
cAMP responsive element 
binding protein 1 -- -- CREB1 Nucleus 
transcriptio
n regulator 1385 12912 
CTSS cathepsin S -- -- CTSS Cytoplasm peptidase 1520 13040 
CYP19A1 
cytochrome P450, family 
19, subfamily A, 
polypeptide 1 CYP19A1 -- -- Cytoplasm enzyme 1588 13075 
CYP7B1 
cytochrome P450, family 
7, subfamily B, polypeptide 
1 CYP7B1 -- -- Cytoplasm enzyme 9420 13123 
CYSLTR1 
cysteinyl leukotriene 
receptor 1 -- -- 
CYSLTR
1 
Plasma 
Membrane 
G-protein 
coupled 
receptor 10800 58861 
DCLK1 doublecortin-like kinase 1 DCLK1 -- -- Other kinase 9201 13175 
DDIT3 
DNA-damage-inducible 
transcript 3 -- -- DDIT3 Nucleus 
transcriptio
n regulator 1649 13198 
DIXDC1 DIX domain containing 1 -- -- DIXDC1 Cytoplasm other 85458 330938 
DNAJC1 
DnaJ (Hsp40) homolog, 
subfamily C, member 1 DNAJC1 -- -- Cytoplasm other 64215 13418 
DST dystonin DST -- -- 
Plasma 
Membrane other 667 13518 
DYSF dysferlin DYSF -- -- 
Plasma 
Membrane other 8291 26903 
DYX1C1 
dyslexia susceptibility 1 
candidate 1 DYX1C1 -- -- Nucleus other 161582 67685 
EDEM2 
ER degradation enhancer, 
mannosidase alpha-like 2 -- EDEM2 -- Cytoplasm enzyme 55741 108687 
EIF2B3 
eukaryotic translation 
initiation factor 2B, 
subunit 3 gamma, 58kDa EIF2B3 -- -- Cytoplasm other 8891 108067 
EIF2B4 
eukaryotic translation 
initiation factor 2B, 
subunit 4 delta, 67kDa -- -- EIF2B4 Cytoplasm other 8890 13667 
EIF4G3 
eukaryotic translation 
initiation factor 4 gamma, 
3 EIF4G3 -- -- Cytoplasm 
translation 
regulator 8672 230861 
ELMO1 
engulfment and cell 
motility 1 ELMO1 -- -- Cytoplasm other 9844 140580 
ENTPD1 
ectonucleoside 
triphosphate 
diphosphohydrolase 1 ENTPD1 -- -- 
Plasma 
Membrane enzyme 953 12495 
ERBB3 
erb-b2 receptor tyrosine 
kinase 3 -- ERBB3 -- 
Plasma 
Membrane kinase 2065 13867 
ERBB2IP erbb2 interacting protein ERBB2IP -- -- 
Plasma 
Membrane other 55914 59079 
ESR1 estrogen receptor 1 ESR1 -- -- Nucleus 
ligand-
dependent 
nuclear 
receptor 2099 13982 
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F2RL1 
coagulation factor II 
(thrombin) receptor-like 1 -- F2RL1 -- 
Plasma 
Membrane 
G-protein 
coupled 
receptor 2150 14063 
FAF1 
Fas (TNFRSF6) associated 
factor 1 FAF1 -- -- Nucleus other 11124 14084 
FAIM2 
Fas apoptotic inhibitory 
molecule 2 -- -- FAIM2 
Plasma 
Membrane other 23017 72393 
FBXL20 
F-box and leucine-rich 
repeat protein 20 FBXL20 -- -- Cytoplasm other 84961 72194 
FER 
fer (fps/fes related) 
tyrosine kinase FER -- -- Cytoplasm kinase 2241 14158 
FGD4 
FYVE, RhoGEF and PH 
domain containing 4 FGD4 -- -- Cytoplasm other 121512 224014 
FGF12 fibroblast growth factor 12 FGF12 -- -- 
Extracellula
r Space other 2257 14167 
FSTL1 follistatin-like 1 FSTL1 -- -- 
Extracellula
r Space other 11167 14314 
FTO 
fat mass and obesity 
associated -- FTO -- Nucleus other 79068 26383 
FUCA1 
fucosidase, alpha-L- 1, 
tissue FUCA1 -- FUCA1 Cytoplasm enzyme 2517 71665 
FXN frataxin -- -- FXN Cytoplasm kinase 2395 14297 
GABBR2 
gamma-aminobutyric acid 
(GABA) B receptor, 2 GABBR2 -- -- 
Plasma 
Membrane 
G-protein 
coupled 
receptor 9568 242425 
GABRA2 
gamma-aminobutyric acid 
(GABA) A receptor, alpha 2 GABRA2 -- -- 
Plasma 
Membrane ion channel 2555 14395 
GABRG3 
gamma-aminobutyric acid 
(GABA) A receptor, gamma 
3 GABRG3 -- -- 
Plasma 
Membrane ion channel 2567 14407 
GFRA2 
GDNF family receptor 
alpha 2 GFRA2 -- -- 
Plasma 
Membrane 
transmemb
rane 
receptor 2675 14586 
GLRA3 glycine receptor, alpha 3 GLRA3 -- -- 
Plasma 
Membrane ion channel 8001 110304 
GNAQ 
guanine nucleotide 
binding protein (G 
protein), q polypeptide GNAQ -- -- 
Plasma 
Membrane enzyme 2776 14682 
GOLPH3 
golgi phosphoprotein 3 
(coat-protein) GOLPH3 -- -- Cytoplasm other 64083 66629 
GPHN gephyrin GPHN -- -- 
Plasma 
Membrane enzyme 10243 268566 
GRID1 
glutamate receptor, 
ionotropic, delta 1  GRID1 -- -- 
Plasma 
Membrane 
G-protein 
coupled 
receptor 2894 14803 
HDAC2 histone deacetylase 2 -- -- HDAC2 Nucleus 
transcriptio
n regulator 3066 15182 
HDAC4 histone deacetylase 4 -- -- HDAC4 Nucleus 
transcriptio
n regulator 9759 208727 
HDAC8 histone deacetylase 8 HDAC8 -- HDAC8 Nucleus 
transcriptio
n regulator 55869 70315 
HEY2 
hes-related family bHLH 
transcription factor with 
YRPW motif 2 -- -- HEY2 Nucleus 
transcriptio
n regulator 23493 15214 
HLA-
DRB1 
major histocompatibility 
complex, class II, DR beta 1 
HLA-
DRB1 -- -- Other other 3123  
HLA-E 
major histocompatibility 
complex, class I, E -- -- HLA-E 
Plasma 
Membrane 
transmemb
rane 
receptor 3133 
667803|
15040 
HMBOX1 homeobox containing 1 -- HMBOX1 -- Nucleus 
transcriptio
n regulator 79618 219150 
HTR1E 
5-hydroxytryptamine 
(serotonin) receptor 1E, G 
protein-coupled HTR1E -- -- 
Plasma 
Membrane 
G-protein 
coupled 
receptor 3354 107927 
HTT huntingtin HTT -- -- Cytoplasm 
transcriptio
n regulator 3064 15194 
HUWE1 
HECT, UBA and WWE 
domain containing 1, E3 
ubiquitin protein ligase HUWE1 -- -- Nucleus 
transcriptio
n regulator 10075 59026 
 28 
HYOU1 hypoxia up-regulated 1 -- HYOU1 -- Cytoplasm other 10525 12282 
IFT140 intraflagellar transport 140 IFT140 -- -- 
Extracellula
r Space other 9742 106633 
IGBP1 
immunoglobulin (CD79A) 
binding protein 1 -- IGBP1 -- Cytoplasm 
phosphatas
e 3476 18518 
IL1RAPL1 
interleukin 1 receptor 
accessory protein-like 1 IL1RAPL1 -- -- 
Plasma 
Membrane 
transmemb
rane 
receptor 11141 331461 
IL1RN 
interleukin 1 receptor 
antagonist -- IL1RN -- 
Extracellula
r Space cytokine 3557 16181 
JARID2 
jumonji, AT rich interactive 
domain 2 JARID2 -- -- Nucleus 
transcriptio
n regulator 3720 16468 
KALRN kalirin, RhoGEF kinase KALRN -- -- Cytoplasm kinase 8997 545156 
KCNJ6 
potassium channel, 
inwardly rectifying 
subfamily J, member 6 KCNJ6 -- -- 
Plasma 
Membrane ion channel 3763 16522 
KDM6A 
lysine (K)-specific 
demethylase 6A KDM6A -- -- Nucleus other 7403 22289 
KIF15 kinesin family member 15 KIF15 -- -- Nucleus other 56992 209737 
LAMA2 laminin, alpha 2 LAMA2 -- -- 
Extracellula
r Space other 3908 16773 
LEF1 
lymphoid enhancer-
binding factor 1 LEF1 -- -- Nucleus 
transcriptio
n regulator 51176 16842 
LEPR leptin receptor LEPR -- LEPR 
Plasma 
Membrane 
transmemb
rane 
receptor 3953 16847 
LFNG 
LFNG O-fucosylpeptide 3-
beta-N-
acetylglucosaminyltransfer
ase -- -- LFNG Cytoplasm enzyme 3955 16848 
LILRB3 
leukocyte 
immunoglobulin-like 
receptor, subfamily B (with 
TM and ITIM domains),  3 -- -- LILRB3 
Plasma 
Membrane 
transmemb
rane 
receptor 11025 
18733|1
8726|18
729|187
25|1872
2|10003
8909|10
0041146 
LOC4400
40 
glutamate receptor, 
metabotropic 5 
pseudogene 
LOC4400
40 -- -- Other other 440040  
LPAR4 
lysophosphatidic acid 
receptor 4 -- -- LPAR4 
Plasma 
Membrane other 2846 78134 
LPIN1 lipin 1 LPIN1 -- -- Nucleus 
phosphatas
e 23175 14245 
LRP2 
low density lipoprotein 
receptor-related protein 2 LRP2 -- -- 
Plasma 
Membrane transporter 4036 14725 
LRP4 
low density lipoprotein 
receptor-related protein 4 LRP4 -- -- 
Extracellula
r Space other 4038 228357 
LRPAP1 
low density lipoprotein 
receptor-related protein 
associated protein 1 -- LRPAP1 -- 
Plasma 
Membrane 
transmemb
rane 
receptor 4043 16976 
LRRC4C 
leucine rich repeat 
containing 4C LRRC4C -- -- 
Plasma 
Membrane other 57689 241568 
LRRK2 
leucine-rich repeat kinase 
2 LRRK2 -- -- Cytoplasm kinase 120892 66725 
MAPK1 
mitogen-activated protein 
kinase 1 MAPK1 -- -- Cytoplasm kinase 5594 26413 
MFN2 mitofusin 2 MFN2 -- -- Cytoplasm enzyme 9927 170731 
MKKS 
McKusick-Kaufman 
syndrome -- -- MKKS Cytoplasm other 8195 59030 
MKL1 
megakaryoblastic 
leukemia (translocation) 1 MKL1 -- -- Nucleus 
transcriptio
n regulator 57591 223701 
MKS1 Meckel syndrome, type 1 MKS1 -- -- Cytoplasm other 54903 380718 
MOS 
v-mos Moloney murine 
sarcoma viral oncogene 
homolog -- -- MOS Cytoplasm kinase 4342 17451 
MS4A1 
membrane-spanning 4-
domains, subfamily A, -- MS4A1 -- 
Plasma 
Membrane other 931 12482 
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member 1 
MSH2 mutS homolog 2 MSH2 -- -- Nucleus enzyme 4436 17685 
MTOR 
mechanistic target of 
rapamycin 
(serine/threonine kinase) MTOR -- -- Nucleus kinase 2475 56717 
MYH9 
myosin, heavy chain 9, 
non-muscle -- -- MYH9 Cytoplasm other 4627 17886 
MYH10 
myosin, heavy chain 10, 
non-muscle MYH10 -- -- Cytoplasm other 4628 77579 
MYO1B myosin IB -- -- MYO1B Cytoplasm other 4430 17912 
MYO5A 
myosin VA (heavy chain 
12, myoxin) MYO5A -- -- Cytoplasm enzyme 4644 17918 
NBAS 
neuroblastoma amplified 
sequence NBAS -- -- Nucleus other 51594 71169 
NCOR1 
nuclear receptor 
corepressor 1 NCOR1 -- -- Nucleus 
transcriptio
n regulator 9611 20185 
NDUFA9 
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 9, 39kDa -- -- 
NDUFA
9 Cytoplasm enzyme 4704 66108 
NEU1 
sialidase 1 (lysosomal 
sialidase) -- -- NEU1 Cytoplasm enzyme 4758 18010 
NFATC3 
nuclear factor of activated 
T-cells, cytoplasmic, 
calcineurin-dependent 3 NFATC3 -- -- Nucleus 
transcriptio
n regulator 4775 18021 
NIPBL 
Nipped-B homolog 
(Drosophila) NIPBL -- -- Nucleus 
transcriptio
n regulator 25836 71175 
NPEPPS 
aminopeptidase 
puromycin sensitive NPEPPS -- -- Cytoplasm peptidase 9520 19155 
NPM1 
nucleophosmin (nucleolar 
phosphoprotein B23, 
numatrin) NPM1 -- -- Nucleus 
transcriptio
n regulator 4869 18148 
NR1H2 
nuclear receptor subfamily 
1, group H, member 2 -- -- NR1H2 Nucleus 
ligand-
dependent 
nuclear 
receptor 7376 22260 
NRCAM 
neuronal cell adhesion 
molecule NRCAM -- -- 
Plasma 
Membrane other 4897 319504 
NRXN1 neurexin 1 NRXN1 -- -- 
Plasma 
Membrane transporter 9378 18189 
NRXN2 neurexin 2 NRXN2 -- -- 
Plasma 
Membrane transporter 9379 18190 
NUSAP1 
nucleolar and spindle 
associated protein 1 -- -- 
NUSAP
1 Nucleus other 51203 108907 
OCLN occludin OCLN -- -- 
Plasma 
Membrane enzyme 
1005066
58 18260 
OMP olfactory marker protein -- OMP -- Cytoplasm other 4975 18378 
OPHN1 oligophrenin 1 OPHN1 -- -- Cytoplasm other 4983 94190 
ORC6 
origin recognition 
complex, subunit 6 ORC6 -- -- Nucleus other 23594 56452 
OTOGL otogelin-like OTOGL -- -- Other other 283310 628870 
OXT 
oxytocin/neurophysin I 
prepropeptide -- OXT -- 
Extracellula
r Space other 5020 18429 
PARD3 
par-3 family cell polarity 
regulator PARD3 -- -- 
Plasma 
Membrane other 56288 93742 
PARG 
poly (ADP-ribose) 
glycohydrolase PARG PARG -- Cytoplasm enzyme 8505 26430 
PARK2 
parkin RBR E3 ubiquitin 
protein ligase PARK2 -- -- Cytoplasm enzyme 5071 50873 
PARK7 parkinson protein 7 -- PARK7 -- Nucleus enzyme 11315 57320 
PARP1 
poly (ADP-ribose) 
polymerase 1 PARP1 -- -- Nucleus enzyme 142 11545 
PBX3 
pre-B-cell leukemia 
homeobox 3 PBX3 -- -- Nucleus 
transcriptio
n regulator 5090 18516 
PCMT1 
protein-L-isoaspartate (D-
aspartate) O-
methyltransferase PCMT1 -- -- Cytoplasm enzyme 5110 18537 
PCSK5 proprotein convertase PCSK5 -- -- Extracellula peptidase 5125 18552 
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subtilisin/kexin type 5 r Space 
PDE11A phosphodiesterase 11A PDE11A -- -- Cytoplasm enzyme 50940 241489 
PDE4D 
phosphodiesterase 4D, 
cAMP-specific  PDE4D -- -- Other enzyme 5144 238871 
PDE9A phosphodiesterase 9A -- -- PDE9A Cytoplasm enzyme 5152 18585 
PDGFRA 
platelet-derived growth 
factor receptor, alpha 
polypeptide PDGFRA -- -- 
Plasma 
Membrane kinase 5156 18595 
PDS5B 
PDS5 cohesin associated 
factor B PDS5B -- -- Nucleus other 23047 100710 
PDXDC2P 
pyridoxal-dependent 
decarboxylase domain 
containing 2, pseudogene -- PDXDC2P -- Other other 283970  
PEX5 
peroxisomal biogenesis 
factor 5 PEX5 -- -- Cytoplasm 
transmemb
rane 
receptor 5830 19305 
PHB prohibitin -- PHB -- Nucleus 
transcriptio
n regulator 5245 18673 
PHC2 
polyhomeotic homolog 2 
(Drosophila) -- PHC2 -- Nucleus other 1912 54383 
PHF8 PHD finger protein 8 PHF8 -- -- Nucleus enzyme 23133 320595 
PIGL 
phosphatidylinositol 
glycan anchor 
biosynthesis, class L PIGL -- -- Cytoplasm enzyme 9487 327942 
PIGV 
phosphatidylinositol 
glycan anchor 
biosynthesis, class V -- -- PIGV Cytoplasm enzyme 55650 230801 
PLCB4 phospholipase C, beta 4 PLCB4 -- -- Cytoplasm enzyme 5332 18798 
PNKD 
paroxysmal nonkinesigenic 
dyskinesia -- -- PNKD Nucleus other 25953 56695 
PNPT1 
polyribonucleotide 
nucleotidyltransferase 1 PNPT1 -- -- Cytoplasm enzyme 87178 71701 
POLA1 
polymerase (DNA 
directed), alpha 1, catalytic 
subunit POLA1 -- -- Nucleus enzyme 5422 18968 
POR 
P450 (cytochrome) 
oxidoreductase POR -- -- Cytoplasm enzyme 5447 18984 
PPARD 
peroxisome proliferator-
activated receptor delta PPARD PPARD -- Nucleus 
ligand-
dependent 
nuclear 
receptor 5467 19015 
PRKG1 
protein kinase, cGMP-
dependent, type I PRKG1 -- -- Cytoplasm kinase 5592 19091 
PRPH2 
peripherin 2 (retinal 
degeneration, slow) -- -- PRPH2 
Plasma 
Membrane 
transmemb
rane 
receptor 5961 19133 
PSEN1 presenilin 1 PSEN1 -- PSEN1 
Plasma 
Membrane peptidase 5663 19164 
PTPN9 
protein tyrosine 
phosphatase, non-
receptor type 9 PTPN9 -- -- Cytoplasm 
phosphatas
e 5780 56294 
PTPN12 
protein tyrosine 
phosphatase, non-
receptor type 12 -- PTPN12 -- Cytoplasm 
phosphatas
e 5782 19248 
PTPRD 
protein tyrosine 
phosphatase, receptor 
type, D PTPRD -- -- 
Plasma 
Membrane 
phosphatas
e 5789 19266 
PUS1 
pseudouridylate synthase 
1 -- PUS1 -- Nucleus enzyme 80324 56361 
RAB7A 
RAB7A, member RAS 
oncogene family RAB7A -- RAB7A Cytoplasm enzyme 7879 19349 
RAD54L RAD54-like (S. cerevisiae) -- RAD54L -- Nucleus enzyme 8438 19366 
RANBP2 RAN binding protein 2 RANBP2 -- -- Other other 5903 19386 
RBL1 retinoblastoma-like 1 RBL1 -- RBL1 Nucleus 
transcriptio
n regulator 5933 19650 
REEP1 
receptor accessory protein 
1 -- REEP1 -- Cytoplasm other 65055 52250 
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RGS11 
regulator of G-protein 
signaling 11 -- -- RGS11 
Plasma 
Membrane enzyme 8786 50782 
RLBP1 
retinaldehyde binding 
protein 1 -- -- RLBP1 Cytoplasm transporter 6017 19771 
RMND1 
required for meiotic 
nuclear division 1 homolog 
(S. cerevisiae) RMND1 RMND1 -- Cytoplasm other 55005 66084 
RNF135 ring finger protein 135 RNF135 -- -- Cytoplasm enzyme 84282 71956 
ROBO2 
roundabout, axon 
guidance receptor, 
homolog 2 (Drosophila) ROBO2 -- -- 
Plasma 
Membrane 
transmemb
rane 
receptor 6092 268902 
RORA 
RAR-related orphan 
receptor A RORA -- -- Nucleus 
ligand-
dependent 
nuclear 
receptor 6095 19883 
RPGRIP1L RPGRIP1-like RPGRIP1L -- -- Cytoplasm other 23322 244585 
RTTN rotatin RTTN -- -- Other other 25914 246102 
SCN8A 
sodium channel, voltage 
gated, type VIII alpha 
subunit SCN8A -- -- 
Plasma 
Membrane ion channel 6334 20273 
SEC24D SEC24 family member D SEC24D -- 
SEC24
D Cytoplasm transporter 9871 69608 
SERAC1 
serine active site 
containing 1 SERAC1 -- -- 
Extracellula
r Space other 84947 321007 
SHANK2 
SH3 and multiple ankyrin 
repeat domains 2 SHANK2 -- -- 
Plasma 
Membrane other 22941 210274 
SIL1 
SIL1 nucleotide exchange 
factor SIL1 -- -- Cytoplasm transporter 64374 81500 
SLC16A2 
solute carrier family 16, 
member 2 (thyroid 
hormone transporter) -- SLC16A2 -- 
Plasma 
Membrane transporter 6567 20502 
SLC17A5 
solute carrier family 17 
(acidic sugar transporter), 
member 5 SLC17A5 SLC17A5 -- 
Plasma 
Membrane transporter 26503 235504 
SLC25A12 
solute carrier family 25 
(aspartate/glutamate 
carrier), member 12 
SLC25A1
2 
SLC25A1
2 
SLC25A
12 Cytoplasm transporter 8604 78830 
SLC30A10 
solute carrier family 30, 
member 10 
SLC30A1
0 -- -- Other transporter 55532 226781 
SLMAP 
sarcolemma associated 
protein -- SLMAP -- 
Plasma 
Membrane other 7871 83997 
SMAD2 SMAD family member 2 -- -- SMAD2 Nucleus 
transcriptio
n regulator 4087 17126 
SMO 
smoothened, frizzled class 
receptor -- -- SMO 
Plasma 
Membrane 
G-protein 
coupled 
receptor 6608 319757 
SNTB2 
syntrophin, beta 2 
(dystrophin-associated 
protein A1, 59kDa, basic 
component 2) SNTB2 -- -- 
Plasma 
Membrane other 6645 20650 
SNX2 sorting nexin 2 SNX2 -- -- Cytoplasm transporter 6643 67804 
SPRN 
shadow of prion protein 
homolog (zebrafish) -- -- SPRN Other other 503542 212518 
SPTBN1 
spectrin, beta, non-
erythrocytic 1 SPTBN1 -- -- 
Plasma 
Membrane other 6711 20742 
SPTLC1 
serine 
palmitoyltransferase, long 
chain base subunit 1 SPTLC1 -- -- Cytoplasm enzyme 10558 268656 
STAR 
steroidogenic acute 
regulatory protein -- -- STAR Cytoplasm transporter 6770 20845 
SV2C 
synaptic vesicle 
glycoprotein 2C SV2C -- -- 
Plasma 
Membrane other 22987 75209 
SYNE2 
spectrin repeat containing, 
nuclear envelope 2 SYNE2 -- -- Nucleus other 23224 319565 
SYTL4 synaptotagmin-like 4 SYTL4 -- -- Cytoplasm transporter 94121 27359 
TACC2 
transforming, acidic coiled-
coil containing protein 2 TACC2 -- -- Nucleus other 10579 57752 
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TACR3 tachykinin receptor 3 -- TACR3 -- 
Plasma 
Membrane 
G-protein 
coupled 
receptor 6870 21338 
TAF1 
TAF1 RNA polymerase II, 
TATA box binding protein 
(TBP)-associated factor, 
250kDa TAF1 TAF1 TAF1 Nucleus 
transcriptio
n regulator 6872 270627 
TAOK1 TAO kinase 1 TAOK1 -- -- Cytoplasm kinase 57551 216965 
TDRD7 tudor domain containing 7 -- -- TDRD7 Cytoplasm other 23424 100121 
TENM4 
teneurin transmembrane 
protein 4 TENM4 -- TENM4 
Plasma 
Membrane other 26011 23966 
TFAP2B 
transcription factor AP-2 
beta (activating enhancer 
binding protein 2 beta) -- TFAP2B -- Nucleus 
transcriptio
n regulator 7021 21419 
TIMD4 
T-cell immunoglobulin and 
mucin domain containing 4 TIMD4 -- -- 
Plasma 
Membrane other 91937 276891 
TMC1 
transmembrane channel-
like 1 TMC1 -- TMC1 
Plasma 
Membrane ion channel 117531 13409 
TRA T cell receptor alpha locus TRA -- -- 
Plasma 
Membrane 
transmemb
rane 
receptor 6955 21473 
TRIOBP 
TRIO and F-actin binding 
protein -- -- TRIOBP Nucleus other 11078 110253 
TRPM6 
transient receptor 
potential cation channel, 
subfamily M, member 6 TRPM6 -- -- 
Plasma 
Membrane kinase 140803 225997 
TRPV1 
transient receptor 
potential cation channel, 
subfamily V, member 1 -- -- TRPV1 
Plasma 
Membrane ion channel 7442 193034 
TRPV3 
transient receptor 
potential cation channel, 
subfamily V, member 3 -- TRPV3 -- 
Plasma 
Membrane ion channel 162514 246788 
UBE4B ubiquitination factor E4B -- UBE4B -- Cytoplasm other 10277 63958 
UBR1 
ubiquitin protein ligase E3 
component n-recognin 1 UBR1 -- UBR1 Cytoplasm enzyme 197131 22222 
UBR2 
ubiquitin protein ligase E3 
component n-recognin 2 UBR2 -- UBR2 Nucleus other 23304 224826 
UGT1A3 
UDP 
glucuronosyltransferase 1 
family, polypeptide A3 -- UGT1A3 -- Cytoplasm enzyme 54659 22236 
ULK1 
unc-51 like autophagy 
activating kinase 1 -- -- ULK1 Cytoplasm kinase 8408 22241 
ULK4 unc-51 like kinase 4 ULK4 -- -- Other kinase 54986 209012 
UNC13B 
unc-13 homolog B (C. 
elegans) UNC13B -- -- Cytoplasm other 10497 22249 
USF1 
upstream transcription 
factor 1 -- -- USF1 Nucleus 
transcriptio
n regulator 7391 22278 
UTRN utrophin UTRN -- -- 
Plasma 
Membrane 
transmemb
rane 
receptor 7402 22288 
VAMP7 
vesicle-associated 
membrane protein 7 VAMP7 -- -- Cytoplasm transporter 6845 20955 
VAPB 
VAMP (vesicle-associated 
membrane protein)-
associated protein B and C VAPB -- -- 
Plasma 
Membrane other 9217 56491 
VAV2 
vav 2 guanine nucleotide 
exchange factor VAV2 -- -- Cytoplasm 
transcriptio
n regulator 7410 22325 
VEZT 
vezatin, adherens 
junctions transmembrane 
protein VEZT -- -- 
Plasma 
Membrane other 55591 215008 
VPS35 
vacuolar protein sorting 35 
homolog (S. cerevisiae) -- VPS35 VPS35 Cytoplasm transporter 55737 65114 
WDR62 WD repeat domain 62 WDR62 -- WDR62 Nucleus other 284403 233064 
XK X-linked Kx blood group XK -- -- 
Plasma 
Membrane transporter 7504 22439 
YARS tyrosyl-tRNA synthetase YARS -- -- Cytoplasm enzyme 8565 107271 
YWHAE tyrosine 3- -- YWHAE -- Cytoplasm other 7531 22627 
 33 
monooxygenase/tryptoph
an 5-monooxygenase 
activation protein, epsilon 
ZDHHC9 
zinc finger, DHHC-type 
containing 9 -- ZDHHC9 -- Cytoplasm enzyme 51114 208884 
ZDHHC15 
zinc finger, DHHC-type 
containing 15 ZDHHC15 -- -- Cytoplasm enzyme 158866 108672 
ZEB1 
zinc finger E-box binding 
homeobox 1 ZEB1 -- -- Nucleus 
transcripti
on 
regulator 6935 21417 
 
Table S3. Enrichment of SVA-associated gene functions in IPA knowledge base categories. 
Functional groups directly attributed to neuronal function are highlighted. A. Canonical 
pathways. B. Functional Networks. C. Diseases and Functions. 
Ingenuity Canonical 
Pathways 
p-value A. Molecules in Pathways 
Cardiac β-adrenergic 
Signaling 
1.04E-01 CACNA1D,PDE3A,PPP2R3B,CACNA1C,AKAP6,PPP1R3A,PDE4B,PPP
1R14B,PDE4D,PPP2R5A,AKAP13,ADCY1, 
PDE8B,GNG2,PPP2R5E,GNG12 
Synaptic Long Term 
Potentiation 
1.14E-01 MAPK1,GRM1,GRM3,CACNA1C,PPP1R3A,GRM4,CREB5,PPP1R14B
,ADCY1,PRKCE,PRKD3,CAMK2B,GRIA3 
Synaptic Long Term 
Depression 
9.46E-02 NOS1,GRID1,MAPK1,GRM3,GRM1,PLA2R1,GUCY2F, 
PRKCE,PPP2R3B,PPP2R5E,GRM4,PRKD3,PPP2R5A,GRIA3 
Axonal Guidance 
Signaling 
6.98E-02 FYN,LRRC4C,GLI2,MAPK1,EPHB2,NFATC3,PIK3R1, 
SEMA4F,WNT2,EIF4E,EPHB1,WASL,SRGAP1,UNC5D, PRKCE, 
ROBO2,SHANK2,PRKD3,GNG12,GLIS1, ITGB1, SEMA3E, 
SRGAP3,SEMA6D,FZD3,PIK3CB,GNG2, SEMA4B, WNT5A,NRP1 
Neuropathic Pain 
Signaling In Dorsal 
Horn Neurons 
1.07E-01 CAMK1D,MAPK1,GRM1,GRM3,PIK3R1,PRKCE,KCNQ3, 
PIK3CB,GRM4,PRKD3,GRIA3,CAMK2B 
CREB Signaling in 
Neurons 
7.96E-02 MAPK1,GRM1,GRM3,PIK3R1,GRIK3,GRM4,CREB5, 
GRID1,ADCY1,PRKCE,PIK3CB,GNG2,PRKD3,GNG12,CAMK2B, 
GRIA3 
Amyotrophic Lateral 
Sclerosis Signaling 
9.17E-02 CAPN5,NOS1,CACNA1D,GRID1,HECW1,PIK3R1,GRIK3, 
CACNA1C,PIK3CB,NAIP,GRIA3 
TR/RXR Activation 1.04E-01 RAB3B,AKR1C1/AKR1C2,SLC2A1,PIK3R1,NCOA1,THRA, 
PIK3CB,THRB,NCOA3,PPARGC1A 
Hypoxia Signaling in the 
Cardiovascular System 
1.23E-01 BIRC6,UBE2V2,UBE2E2,UBE2E3,CREB5,UBE2E1,PTEN, ARNT 
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Breast Cancer 
Regulation by 
Stathmin1 
7.69E-02 CAMK1D,MAPK1,PIK3R1,PPP2R3B,PPP1R3A,TRPC5, 
PPP1R14B,PPP2R5A,ADCY1,PRKCE,PIK3CB,GNG2, 
PPP2R5E,PRKD3,GNG12,CAMK2B 
Renal Cell Carcinoma 
Signaling 
1.08E-01 MET,ETS1,SLC2A1,MAPK1,CUL2,PIK3R1,PIK3CB,ARNT 
PKCθ Signaling in T 
Lymphocytes 
7.75E-02 MAP3K15,FYN,POU2F1,MAPK1,NFATC3,VAV3,PIK3R1, 
CD86,PIK3CB,CARD11,CAMK2B 
Dopamine-DARPP32 
Feedback in cAMP 
Signaling 
7.49E-02 NOS1,CACNA1D,CSNK1G3,CACNA1C,PPP2R3B,PPP1R3A,CREB5, 
PPP1R14B,PPP2R5A,ADCY1,PRKCE,KCNJ6, PPP2R5E,PRKD3 
Glutamate Receptor 
Signaling 
1.01E-01 GRID1,GRM1,GRM3,GRIK3,GRM4,GNG2,GRIA3 
AMPK Signaling 7.23E-02 PFKFB3,KAT2B,ACACB,MAPK1,PIK3R1,PRKAA2,PPP2R3B,PIK3CB, 
CFTR,PPP2R5E,AK2,PPP2R5A 
Actin Cytoskeleton 
Signaling 
7.05E-02 ITGB1,MPRIP,MAPK1,PIK3R1,FGF14,TRIO,WASL,PIP5K1C,VAV3, 
DIAPH2,PIK3CB,WASF2,SSH2,NCKAP1L, 
ARHGAP24,GNG12,IQGAP3 
Clathrin-mediated 
Endocytosis Signaling 
7.69E-02 ITGB1,MYO6,AP2B1,APOB,EPS15,EPHB2,PIK3R1,FGF14, 
ITGB8,HIP1,MET,WASL,PIP5K1C,PIK3CB,MYO1E 
ERK/MAPK Signaling 7.35E-02 PPARG,ITGB1,ETS1,FYN,MAPK1,PIK3R1,PPP2R3B, 
PPP1R3A,CREB5,PPP1R14B,PPP2R5A,EIF4E,PRKCE, 
PIK3CB,PPP2R5E 
Virus Entry via 
Endocytic Pathways 
9E-02 ITGB1,FLNB,AP2B1,FYN,PIK3R1,PRKCE,PIK3CB,ITGB8, PRKD3 
Fcγ Receptor-mediated 
Phagocytosis in 
Macrophages and 
Monocytes 
8.82E-02 FYN,MAPK1,VAV3,PIK3R1,DGKB,PRKCE,FYB, PRKD3, PTEN 
Antiproliferative Role of 
Somatostatin Receptor 
2 
9.86E-02 NOS1,MAPK1,PIK3R1,GUCY2F,PIK3CB,GNG2,GNG12 
cAMP-mediated 
signaling 
7.31E-02 MAPK1,CAMK1D,GRM3,PDE3A,AKAP6,PDE4B,GRM4, 
CREB5,PDE4D,CNGA1,AKAP13,FSHR,ADCY1,P2RY12, 
PDE8B,CAMK2B 
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Production of Nitric 
Oxide and Reactive 
Oxygen Species in 
Macrophages 
6.67E-02 MAP3K15,APOB,MAPK1,PIK3R1,PPP2R3B,PPP1R3A, 
NCF4,PPP1R14B,PPP2R5A,RHOT1,PRKCE,PIK3CB, PPP2R5E,PRKD3 
Glioma Signaling 8.04E-02 CAMK1D,MAPK1,PIK3R1,PRKCE,PIK3CB,RBL1,PRKD3, 
PTEN,CAMK2B 
DNA Double-Strand 
Break Repair by 
Homologous 
Recombination 
1.76E-01 ATRX,RAD52,BRCA1 
Semaphorin Signaling 
in Neurons 
1.15E-01 ITGB1,MET,FYN,MAPK1,RHOT1,NRP1 
Macropinocytosis 
Signaling 
9.21E-02 ITGB1,MET,PIK3R1,PRKCE,PIK3CB,ITGB8,PRKD3 
Relaxin Signaling 7.01E-02 MAPK1,PDE3A,PIK3R1,ADCY1,GUCY2F,PDE8B,PIK3CB, 
PDE4B,GNG2,PDE4D,GNG12 
Rac Signaling 7.38E-02 ITGB1,NOX4,MAPK1,PIP5K1C,PIK3R1,PIK3CB,PARD3, 
IQGAP3,ANK1 
CDK5 Signaling 8.51E-02 ITGB1,MAPK1,ADCY1,PPP2R3B,PPP1R3A,PPP2R5E, 
PPP1R14B,PPP2R5A 
CDK5 Signaling 8.51E-02 ITGB1,MAPK1,ADCY1,PPP2R3B,PPP1R3A,PPP2R5E, 
PPP1R14B,PPP2R5A 
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Categories 
Diseases or 
Functions 
Annotation 
p-Value B. Molecules in Diseases and Functions 
Cardiovascular Disease coronary 
artery disease 
1.77E-06 AGPAT5,AKAP13,ASTN2,CACNA1C,CACNA1D, 
CACNA2D1,CAMTA1,CNTN5,CSMD1,CSMD2, 
CTNNBL1,EIF4G3,ESR2,GABRA2,GABRB1, 
KDM1A,KIAA0319L,LRP1 (includes EG:16971), 
MEF2A,OGDH,P2RY12,PDE3A,PDE4B, PDE4D, 
PPARG,SGCD,TMEM163,WWOX 
Endocrine System 
Development and 
Function 
glucose 
tolerance 
1.42E-05 ABCC9,ARNT,CACNA1D,CADPS2,CASP8,CREB5, 
EIF2AK3,FAM3B,LRP1 (includes 
EG:16971),MGAT4A,NOS1,PAM,PDK4,PIK3CB, 
PIK3R1,PPARG,PPARGC1A,PPP1R3A,PRKAA2, 
PTEN,RPH3AL,SERPINA12,SGK3,SLC30A8, THRA 
(includes EG:21833) 
Cellular Assembly and 
Organization, Cellular 
Function and 
Maintenance, Nucleic 
Acid Metabolism 
AGPAT2,ALMS1,AP1AR,ARHGAP23,ATP5A1,ATP5B, 
ATPAF1,CGRRF1,CREB3,EDEM2,EXOC6B,EXPH5,FILIP1, 
GGA1 (includes EG:106039), HSF1,JMJD6,MEPCE, 
MSTO1,NR1H3,PHRF1,RAB27A,RAD23A,RAE1,RALA, 
RPAP1,RPS3A,S100PBP,SLC30A9,SMAD9,UBC,VKORC1L1,W
DR5,WDR48,WDR59,WDR70 
17 16 
Cell Cycle, Hereditary 
Disorder, Neurological 
Disease 
AKAP11,CCHCR1,CNOT8,DEGS1,EIF5,ESF1,FAM21A, 
IQGAP3,KIAA0196,KIAA1033,KLHDC4,KNTC1,LEPRE1, 
NBAS,POLD2,PRR12,PUM1,RINT1,SCFD2,SEC61A1, 
SEC61A2,SEC61G,SERPINA12,SLC39A14,STT3A,TSSC1, 
TUSC3,TXNDC12,UBC,USP3,WASH1/WASH5P,WDTC1, 
YTHDF2,ZW10,ZWILCH 
17 16 
Lipid Metabolism, 
Nucleic Acid 
Metabolism, Small 
Molecule Biochemistry 
ACAD9,ACAD10,ACADSB,AGPAT3,AGPAT4,AGPAT5, 
AGPAT6,CLPP,DDX46,DDX47,EFTUD1,FRYL,GFM2, 
GPR107,GPR108,GPR119,GPR155,GPR158,GPR176, 
GPR179,GPR89A/GPR89B,GPR89C,GPRC5C,HECW1, 
ITFG1,LGR4,NTSR1,OLA1,PCNX,SCAF11,SH2D4A,SUCLG2, 
TRAPPC12,UBC,ZNF277 
17 16 
Organ Morphology, 
Reproductive System 
Development and 
Function, Tissue 
Morphology 
ADAMTS19,ALDH5A1,AQP8,AR,CRISP1,CUX2,DMRT1, 
DMRTC2,DMRTC1/DMRTC1B,EPB41L4B,FAM110B, 
FGFR2,GLCCI1,GLIPR1,GPR65,GUCY2F,HOXD1,HS6ST2, 
KBTBD11,KLK11,KLK14,MED12L,MSMB,MTL5,NLRP10 
,NR3C1,PATZ1,PHF3,RAD54L2,RBMS3,SAR1B,SEMA5B, 
SPINLW1,TGFB1 (includes EG:21803),TPST2 
17 16 
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Cell Morphology, 
Cellular Assembly and 
Organization, Cellular 
Development, Cellular 
Function and 
Maintenance, 
Embryonic 
Development, Nervous 
System Development 
and Function, Tissue 
Development, Tissue 
Morphology 
morphology of 
dendritic 
spines 
1.93E-05 CTNNA2,EPHB1,EPHB2,LRRC7,MAGI2,OPHN1 
Cellular Movement, 
Nervous System 
Development and 
Function 
guidance of 
axons 
6.93E-05 ALCAM,APBB2,CDH4,CNTN4,EPHB1,EPHB2,FEZ2
, GLI2,LRRC4C,MAPK1,NRP1 (includes 
EG:18186),OPHN1,PLXNA4,RELN,ROBO2,RUNX3
, SEMA4F,VAV3 
Cellular Function and 
Maintenance 
function of 
enterocytes 
7.37E-05 ESR2,MYD88,THRA (includes EG:21833) 
Connective Tissue 
Disorders 
Dupuytren 
contracture 
1.69E-04 ADAMTS16,ADAMTS18,ADAMTS19,ADAMTS3, 
ADAMTS6,ADAMTS9,COL14A1, COL19A1 
(includes 
EG:12823),COL21A1,COL22A1,COL24A1 
Nervous System 
Development and 
Function 
development 
of central 
nervous 
system 
1.70E-04 ABR,APBB2,ATG7,ATRX,CDCA7L,CTNNA2,DAB1, 
EPHB2,ESR2,FOXJ3,FYN,FZD3,GLI2,HESX1, 
IL1RAPL1,IL1RAPL2,KHDRBS1,KIF2A,MAPK1, 
MCPH1 (includes EG:244329),MET,NDST3, 
NDUFS4,NPAS2,NPAS3, PARD3,PCSK6,PLXNA4, 
PPARG,PTEN,RBL1,RELN, REST,ROBO2,RORA, 
SHROOM4,SLC4A7,SOX6, SPTBN1,ST8SIA4, 
STK4,THRA (includes EG:21833),TOP2B,TRIO, 
VSNL1,WASF2,WNT5A, ZEB1 
Cardiovascular Disease, 
Organismal Injury and 
Abnormalities 
variant angina 1.88E-04 CACNA1C,CACNA1D,CACNA2D1,SGCD 
Cell-To-Cell Signaling 
and Interaction 
synaptic 
depression 
2.24E-04 ADCY1,CAMK2B,EPHB1,EPHB2,GRIA3,GRM1, 
GRM3,HIP1 (includes EG:176224), LRRC7,PCLO, 
PIP5K1C, ST8SIA4,SYN3 
Neurological Disease radiculopathy 2.85E-04 CACNA2D1,CACNA2D2,CACNA2D3 
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Organismal Survival organismal 
death 
3.14E-04 ABCC9,ACLY,ADAR,ANKH,ANXA1,APBB2,APOB, 
ARNT,ATG7,BIRC6,BMPR1A,BRCA1,BRD4,            
C4B (includes others),CACNA2D2,CASP8, 
CELF1,CFTR,CLIC4, CUZD1,DAB1,DMD,EHMT2 
,EIF2AK3,ENG,EPHB2, 
ESR2,ETS1,ETV6,FBN1,FLNB, 
FYN,GABRA2,GPR98, HIP1 (includes 
EG:176224),HMGA2, IL4R,IRGM,ITGB1,ITGB8, 
KAT2B,KCNJ6,KIDINS220, 
LRRC7,MAD1L1,MADD, MAGI2,MAPK1,MCPH1 
(includes EG:244329), MEF2A,MET,MGMT, 
MYBL2,MYD88,NCOA1, 
NCOA3,NDUFS4,NFATC3,NOS1,NOVA1,NRP1 
(includes EG:18186),OPHN1, PARP1,PCLO, 
PCSK6,PHC1,PHC2,PIK3CB,PIK3R1, PIP5K1C, 
POU2F1,PPARG,PPARGC1A,PPARGC1B, PTEN, 
PTPRJ,RAB3B,RAD52 (includes EG:19365), RBL1, 
REST, REV3L, SGCD,SIAH1,SLC2A1, SPEN, 
SPRED2, 
SPTBN1,ST8SIA4,STK4,TCF12,TFCP2L1,TFEB, 
THRA (includes EG:21833),THRB,TOP2B, TPMT, 
TRAFD1, TRIM54,TRIO,UBP1 (includes 
EG:100136855), 
USP18,VAV3,WASF2,WASL,WWOX,ZEB1 
Cellular Function and 
Maintenance, Nervous 
System Development 
and Function 
function of 
outer hair cells 
3.27E-04 CACNA1D,GPR98,THRA (includes 
EG:21833),THRB 
Cancer, Hereditary 
Disorder, Reproductive 
System Disease 
tumorigenesis 
of prostatic 
carcinoma 
3.27E-04 HIP1 (includes EG:176224),PPARG,PRKCE,PTEN 
DNA Replication, 
Recombination, and 
Repair 
breakage of 
DNA 
3.66E-04 BRCA1,NOS1,PARP1,PTEN,RAD52 (includes 
EG:19365),REV3L,TOP2B 
Cardiovascular Disease, 
Organismal Injury and 
Abnormalities 
angina 
pectoris 
4.31E-04 CACNA1C,CACNA1D,CACNA2D1,P2RY12,PDE3A, 
PDE4B,PDE4D,PPARG,SGCD 
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Cellular Assembly and 
Organization, Cellular 
Function and 
Maintenance 
organization 
of cytoplasm 
4.49E-04 ABR,ADCY1,ALMS1,ANTXR1,ARHGAP24, 
ARHGAP32,ARHGAP6,ARHGAP8/PRR5-
ARHGAP8,ATG7,ATP7A,CAMK1D,CDH4,CNTN4, 
CTNNA2,CTNND2,DAB1,DIAPH2,EIF2AK3,ENG, 
EPHB1,EPHB2,FHIT,FLNB,FYN,GRM4,HYDIN,ITG
B1,ITGB8,KIDINS220,KIF20B,KIF2A,LRP1 
(includes EG:16971),LRRC4C,LRRC7, MAGI2, 
MAP4,MAPK1, MET,MPRIP,MSTO1,MYD88, 
MYO6,NCKAP1L, NOS1,NPLOC4,NRP1 (includes 
EG:18186), OPHN1,PACSIN2,PAM,PARD3, 
PCDH15, PCLO, PIK3R1,PIP5K1C,PKHD1, 
PLXNA4,PPARG, PPARGC1A, PPARGC1B, 
PRKCE,PTEN,PTPRQ,RALB, RELN, ROBO2, 
RRBP1,RUNX3,SEC16B,SEMA3E, SEMA4F, 
SEPT7,SEPT9,SHROOM3, SHROOM4,SIAH1, 
SSH2,STRN,TFCP2L1,TOP2B, TRIM54,TRIO,TTK, 
VAV3, VPS54, WASF2,WASL,WNT5A 
Nervous System 
Development and 
Function 
morphology of 
nervous 
system 
5.03E-04 ABR,ADCY1,ALPL,APBB2,APOB,BRCA1, 
CACNA1D, CACNA2D2,CADPS2,CD86,CLIC4, 
CNTN4,CTNNA2 ,CUX2,DAB1,ECE1,EPHB1, 
EPHB2, ERBB2IP,ESR2, FAT3,FSHR,FYN,GLI2, 
GRID1, HESX1,IL1RAPL1,IL4R, ITGB1,ITGB8, 
KIDINS220,KIF2A,LRRC7,MADD, MAGI2,MCPH1 
(includes EG:244329),MET,NCOA1, NDST3, 
NDUFS4,NFATC3,NOS1,NPAS3,NRP1 (includes 
EG:18186),OPHN1 ,PCSK6,PLXNA4, PPARGC1A, 
PTEN,RBL1,RELN,ROBO2,SEMA5B,ST8SIA4,THRA 
(includes EG:21833), THRB,TOP2B,TRIO, VAV3, 
WNT5A 
Molecular Transport transport of 
Mg2+ 
5.28E-04 MAGT1,NIPAL1,TUSC3,ZDHHC17 
Neurological Disease hydrocephalus 5.75E-04 APOB,DAB1,ENG,GLI2,ITGB8,OPHN1,PTEN, 
RELN, ST8SIA4,USP18 
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Cellular Assembly and 
Organization, Cellular 
Function and 
Maintenance 
organization 
of 
cytoskeleton 
5.85E-04 ABR,ADCY1,ALMS1,ANTXR1,ARHGAP24, 
ARHGAP32,ARHGAP6,ARHGAP8/PRR5-
ARHGAP8, ATG7,ATP7A,CAMK1D,CDH4,CNTN4, 
CTNNA2, CTNND2,DAB1,DIAPH2,ENG,EPHB1, 
EPHB2, FHIT, FLNB,FYN,GRM4,HYDIN, 
ITGB1,ITGB8, KIDINS220, KIF20B,KIF2A,LRP1 
(includes EG:16971), LRRC4C, LRRC7,MAGI2, 
MAP4,MAPK1, MET,MPRIP, MYD88, MYO6, 
NCKAP1L,NOS1, NRP1 (includes EG:18186), 
OPHN1,PACSIN2, PAM, PARD3,PCDH15,PCLO, 
PIK3R1,PIP5K1C,PKHD1,PLXNA4,PPARG,PPARGC
1B,PRKCE,PTEN,PTPRQ, RALB,RELN, ROBO2, 
RRBP1, RUNX3,SEMA3E, SEMA4F,SEPT7,SEPT9, 
SHROOM3, SHROOM4, SSH2,STRN,TOP2B, 
TRIM54, TRIO, VAV3,VPS54, 
WASF2,WASL,WNT5A 
Cell Cycle, Cellular 
Movement 
cytokinesis of 
tumour cell 
lines 
5.86E-04 BRD4,KIF20B,MASTL,NEDD4L,SEPT7,SEPT9, 
SIAH1, VAV3 
Cardiovascular System 
Development and 
Function 
abnormal 
morphology of 
vasculature 
6.59E-04 ARNT,BIRC6,CLIC4,FBN1,ITGB8,MAPK1,NDUFS4, 
NFATC3,NPAS3,PPARG,PTEN,SLC4A7,STK4, 
UBP1 (includes EG:100136855),WASF2,WNT2 
Cardiovascular System 
Development and 
Function, Embryonic 
Development, 
Organismal 
Development, Tissue 
Development 
vascularization 
of yolk sac 
8.02E-04 ARNT,ITGB8,NRP1 (includes EG:18186),STK4 
Cell Cycle, DNA 
Replication, 
Recombination, and 
Repair 
abnormal 
morphology of 
chromosomes 
9.14E-04 BRCA1,HELLS,MCPH1 (includes EG:244329), 
PARP1,RAD52 (includes EG:19365) 
 41 
Infectious Disease infection by 
Retroviridae 
1.07E-03 ACACB,AKAP13,ANKRD30A,ARHGAP32,ATG7, 
BRCA1,CACNA2D1,CACNA2D2,CACNA2D3, 
CALCOCO1,CAMK1D,CD86,CFTR,CLOCK,DAPK2, 
DMXL1,DYSF,EIF2C3,FDPS,GABRB1,HCP5,IL4R, 
KHDRBS1,KIAA0922,MAP4,NDUFAF2,PCSK6, 
PDE3A ,PDE4B,PDE4D,PHF12,PHF3,PIP5K1C, 
PPARG, PPP2R5E,PTPRJ,PVT1,RALB,RANBP17 
,RNF170, SEMA5B,SLC2A1,SLC2A13, SLC4A7, 
SPEN, SPTBN1, ST3GAL3,SUCLG2, TATDN1, 
TMEM163, TOP2B, TRIM5,UBE2E1, USP26, 
WDTC1,XKR4,ZNF292 
Developmental 
Disorder, Neurological 
Disease 
mental 
retardation 
1.15E-03 ATP7A,ATRX,AUTS2,CTNND2,GRIA3,IL1RAPL1,M
AGT1,OPHN1,SHROOM4,TSPAN7,TUSC3,ZNF599 
Behaviour nest building 
behaviour 
1.16E-03 LRRC7,MAPK1,NDUFS4,NPAS3 
Cardiovascular System 
Development and 
Function, Organ 
Morphology 
abnormal 
morphology of 
heart 
1.23E-03 ACACB,CASP8,ECE1,ESR2,ITGB8,MAPK1, 
NFATC3, NOX4,PHC1,PPARGC1A,PPARGC1B, 
SGCD,SNX27, SPTBN1,TRIM54,UBP1 (includes 
EG:100136855),WASF2,WASL 
Digestive System 
Development and Function, 
Endocrine System 
Development and Function, 
Organ Morphology 
morphology of 
pancreas 
1.25E-03 CACNA1D,CADPS2,CFTR,EIF2AK3,ESR2,GPR39, 
MGMT,MYD88,NFATC3,PKHD1,PPARG,PTEN, 
THRA (includes EG:21833) 
 
Table S4. Link of SVA-associated genes to neural system related ontological categories.  Shading 
represents an association between genes with particular types of SVAs (columns) with certain 
categories (rows). An enrichment in a category with (-log(p-value)>2.9)  is highlighted in purple and 
(-log(p-value)> 4.6), in blue. 
 
SVA type       A B C D E F F1 
Behavioral  
features               
behavior - 
3.754903399
88501 
1.667197019
29576 
7.697397238
39598 - 
2.344704794
37986 2.23 
head tossing - - 
2.226348280
65468 - - - - 
abnormal 
initiation of 
locomotion - - - 
2.186947690
0683 - - - 
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aggressive 
behavior - 
3.185728965
06994 - 
2.991084618
18918 - - - 
aggressive 
behavior 
toward 
females - - - 
3.298076236
17792 - - - 
associative 
memory - - - - - 
2.320805274
09475 - 
auditory 
brainstem 
response - - 
1.751733073
22935 - - - - 
barbering 
behavior - 
2.086058936
35069 - - - - - 
climbing 
ability 
2.911892863
30032 - - - - - - 
climbing 
behavior - 
2.261567369
22413 - - - - - 
coordination - 
2.486817298
98497 - 
3.671823517
82147 - - - 
coordination 
of limb - - 
1.388755605
35539 - - - - 
discriminator
y learning - 
3.582363019
11825 - - 
1.980764558
27166 - - 
facial 
expression - 
2.562014300
10179 - - - - - 
feeding - - - 
2.622274673
61367 - - 1.88 
grooming - 
3.315659261
46307 
2.259801970
67178 
3.158228847
8537 - - - 
learning - 
4.767153158
1683 - 
4.970821572
22324 - - - 
limb 
clasping - - - - - - 2.2 
locomotor 
activity - - - - - - 1.48 
long-term 
spatial 
reference 
memory - - - - - 
2.621328301
31439 - 
mating - - - 
2.297287477
64665 - - - 
mating 
behavior - - - 
2.471905140
59428 - - - 
memory - 
2.452533386
98332 - 
2.208671745
81991 
1.540354384
86205 - - 
mother 
preference - - - - - 
2.621328301
31439 - 
motor 
learning - 
4.173160986
55729 - - - - - 
mounting - - 
2.101827514
05373 - - - - 
movement 
of rodents - - - 
2.330219623
54048 
1.587319530
7674 - - 
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nest building 
behavior - 
3.122032899
94915 - 
3.812587935
44142 - - - 
nursing - - - - - - 1.82 
olfactory 
discriminatio
n - 
3.486212788
45036 - - - - - 
parental 
behavior - - - 
2.854228663
27821 - - - 
passive 
avoidance 
learning 
1.330430037
45532 
2.291582038
99342 - - 
1.351140766
01387 - - 
place 
preference - - - - 
1.362182345
21848 - - 
pup retrieval - - - 
2.569967479
31816 - - - 
sexual 
behavior - - - 
3.218415388
90373 - - - 
sexual 
receptivity of 
female 
organism - - - 
3.124030123
97743 - - - 
short-term 
memory - - - - 
1.595707552
44453 - - 
social 
behavior - 
4.475180901
65667 - 
3.926022584
6134 - 
3.262127805
30914 - 
social 
exploration - 
2.313689067
98083 - - - - - 
social odor 
recognition 
memory - - - - - 
2.621328301
31439 - 
somatosens
ory-
discriminatio
n learning - 
2.562014300
10179 - - - - - 
spatial 
learning - 
3.810127181
76609 - - 
2.896269857
82354 - - 
stress 
response of 
mice - 
3.690747572
10718 - - - - - 
stretching 
behavior - 
2.562014300
10179 - - - - - 
vocalization - - - 
3.080642679
48855 - - - 
walking - - - 
3.486585023
79951 - - 1.5 
Diseases                                                      
SVA type A B C D E F F1 
Alzheimer's 
disease     
2.955157664
3813     
2.521850717
54049   
Bipolar 
disorder       
2.381137923
37015       
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Central 
nervous 
system 
tumor       
4.207456202
72873       
Cerebellar 
ataxia       
3.830254367
49913       
Dementia       
2.741710319
10954       
Depressive 
disorder       
3.689838655
24415       
Epilepsy       
2.679998431
54644   
2.621328301
31439   
Familial 
Parkinson 
disease       
2.357400439
6226   
3.302217920
79955   
Generalized 
seizures       
3.512129272
59493       
Glioma       
4.366043173
11433       
Hereditary 
CNS 
demyelinatin
g disease       
4.476535415
39325       
Huntington's 
Disease   
2.086058936
35069         1.89 
Localization-
related 
epilepsy       
2.964987725
53459       
Malformatio
n of brain 
1.341828435
09574 
7.239868893
40811 
1.575876338
55576 
6.087333935
96778 
2.398010081
87586 
5.395796572
47572   
Mental 
retardation   
5.019777607
52792 
2.263959234
02463 
8.160379619
88198       
Mood 
Disorders       
3.917836339
40726 
2.518413370
92726     
Movement 
Disorders     
8.005333475
70778 
7.875598589
04657     1.96 
neuromuscu
lar disease     
3.757674324
94131 
3.667637361
37556 
1.485696747
13159   2.3 
Parkinson 
disease     
2.702633240
98405 
2.144207046
61376   
2.621328301
31439   
Progressive 
motor 
neuropathy       
3.749594263
46343       
Schizophren
ia   
2.562014300
10179   
2.282254651
94161       
Seizures 
1.739100926
96039     
4.542329338
58452     1.39 
syndromic 
X-linked 
mental 
retardation   
2.562014300
10179   
5.990850662
37035 
3.383827396
38322     
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X linked 
mental 
retardation 
syndromic 
60   
2.911719696
71727   
7.109939844
72082 
2.933082162
39815     
anxiety-like 
behavior   
3.925029459
50205           
Biological 
functions                                     
SVA type A B C D E F F1 
assembly of 
axon initial 
segments - - - 
3.816861309
09647 - - - 
axonogenesi
s - - - - - 
4.188167765
02243 - 
concentratio
n of 
norepinephri
ne - - - - - 
3.382008035
78627 - 
dendritic 
growth/bran
ching - - - 
4.717507994
32237 - - - 
developmen
t of brain - 
7.983344490
39365 - 
13.49993295
86417 - 
6.544090761
47706 1.31 
developmen
t of central 
nervous 
system - - - 
16.26946445
44585 - 
9.614785024
02455 - 
developmen
t of forebrain - 
6.534064123
30348 - 
5.832836449
43782 
1.489640392
29991 
7.019431365
00185 - 
electrophysi
ology of 
nervous 
system - - - 
4.339685048
6171 - - - 
formation of 
cellular 
protrusions - 
3.475098411
94994 - 
12.24694532
53689 - 
2.516623853
6187 - 
long-term 
potentiation - 
2.373604818
13443 - 
2.750895576
68827 
1.499506127
06148 - - 
morphology 
of axons - 
4.010246590
91482 - - - - - 
morphology 
of brain 
1.552518156
1587 
5.744631250
89947 
4.084370551
95381 
10.34069165
60822 - 
7.378516704
96971 - 
morphology 
of forebrain - 
5.353185212
68852 - 
4.951243884
67946 - 
4.615401827
88052 - 
 46 
morphology 
of nervous 
system - 
5.913784607
0663 
4.940595674
78393 
17.89008788
12047 
1.631058230
1263 
8.594051810
98923 - 
morphology 
of 
telencephalo
n 
1.713044747
80371 
5.089354908
36635 
3.407424021
97678 
3.554898029
02982 - 
4.223008640
96256 - 
neuronal cell 
death 
2.064913327
96842 - 
2.699790242
6981 
2.916032420
78867 
1.366443592
3436 
2.277535916
42938 - 
quantity of 
axons - - - 
5.257526106
69274 - - - 
quantity of 
brain cells - - - - - 
5.041556162
70202 - 
synaptic 
depression - 
2.458177425
54262 - 
5.876218658
07706 - - - 
synaptic 
transmission 
4.195834625
77855 - - - - - - 
synaptogen
esis - 
5.506083087
07257 - 
4.001743594
28815 - - - 
neurotransm
ission - 
4.567025574
65991 - 
2.823192936
81402 - 
2.377482448
44698 - 
 
Table S5. Genes grouped by their associated behavioural categories and the SVA-types (a (SVA_A)-
g(SVA_F1)). 
a.SVA_A 
Diseases or Functions Annotation Molecules 
Climbing Ability KCNJ6 
Anxiety GABBR2,KCNJ6,PLCB4 
Passive Avoidance Learning GABBR2 
b.SVA_B 
Diseases or Functions Annotation Molecules 
Learning HDAC4,HTT,MAPK1,NRCAM,NRXN1,OXT,TACR3,UBR1 
Social Behaviour HTT,MAPK1,NRXN1,OXT 
Motor Learning HTT,NRCAM,NRXN1 
Anxiety-Like Behaviour HTT,MAPK1,OXT 
Spatial Learning HDAC4,HTT,NRCAM,TACR3,UBR1 
Behaviour 
CLCN3,HDAC4,HTT,MAPK1,NRCAM,NRXN1,OXT,SEC24D,TA
CR3,UBR1,F1 
Discriminatory Learning HTT,UBR1 
Olfactory Discrimination HTT,OXT 
Grooming HTT,NRXN1,OXT 
Emotional Behaviour HTT,MAPK1,NRXN1,OXT,TACR3 
Aggressive Behaviour HTT,MAPK1,OXT 
Nest Building Behaviour MAPK1,NRXN1 
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Invasive Behaviour NRCAM,SEC24D 
Vertical Rearing HTT,NRCAM,UBR1 
Circadian Rhythm HTT,MAPK1,OXT 
Apathy HTT 
Choreiform Movement HTT 
Facial Expression HTT 
Irritability Of Organism HTT 
Somatosensory-Discrimination 
Learning HTT 
Spasmodic Movement HTT 
Stretching Behaviour HTT 
Memory HDAC4,HTT,MAPK1,OXT 
Hyperactivity HTT,TIMD4 
Social Exploration NRCAM,OXT 
Passive Avoidance Learning TACR3,UBR1 
Climbing Behaviour HTT 
Executive Functioning HTT 
Barbering Behaviour USF1 
c.SVA_C 
Diseases or Functions Annotation Molecules 
Grooming LRRK2,SLC16A2 
Head Tossing ATF2 
Mounting NPEPPS 
Emotional Behaviour LRRK2,MKKS,SLC16A2 
Behaviour ABHD12,ATF2,LRRK2,MKKS,NPEPPS,SLC16A2 
Locomotion ABCA1,FGF12,LRRK2 
d.SVA_D 
Diseases Or Functions Annotation Molecules 
Behaviour ABL2,ATP8A2,CACNB4,CNTNAP2,CYP19A1,ESR1,F2RL1,FTO, 
GFRA2,GNAQ,GPHN,IL1RN,LEPR,LRPAP1,MOS,MTOR,NFATC3, 
NRXN1,OCLN,PARK7,PRKG1,SCN8A,SHANK2,SYTL4, 
TRPV1,UBR1,VEZT 
Cognition ABL2,CNTNAP2,CYP19A1,ESR1,IL1RN,LEPR,LRPAP1,MTOR, 
NIPBL,NRXN1, PARK7,SHANK2 ,UBR1,VEZT 
Learning ABL2,CNTNAP2,CYP19A1,ESR1,IL1RN,LEPR,LRPAP1,MTOR,NRXN
1,PARK7, SHANK2,UBR1, VEZT 
Locomotion ABL2,AGTPBP1,ATP7A,CACNB4,CYP19A1,ESR1,FXN,NFATC3, 
PARK7,PBX3, SCN8A 
Social Behaviour CNTNAP2,IL1RN,NFATC3,NRXN1,SHANK2 
Nest Building Behaviour CNTNAP2,NRXN1,SHANK2 
Walking AGTPBP1,CACNB4,FXN,SCN8A 
Emotional Behaviour ABL2,CNTNAP2,CYP19A1,ESR1,LEPR,NRXN1 ,SHANK2,TRPV1 
Aggressive Behaviour Toward 
Females CYP19A1,ESR1 
Sexual Behaviour ABL2,CYP19A1,ESR1,SYTL4 
Grooming CNTNAP2,CYP19A1,NRXN1,SHANK2 
Sexual Receptivity Of Female CYP19A1,ESR1 
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Organism 
Vocalization CNTNAP2,GPHN,SHANK2 
Aggressive Behaviour ABL2,CYP19A1,ESR1,LEPR 
Parental Behaviour CYP19A1,ESR1,SHANK2 
Feeding ATP8A2,ESR1,FTO,GPHN,IL1RN,LEPR,OCLN 
Pup Retrieval ESR1,SHANK2 
Mating Behaviour ABL2,CYP19A1,ESR1 
Anxiety GABRA2,GABRG3,NFATC3,SHANK2,TRPV1, VAMP7 
Mating CYP19A1,ESR1 
Panic-Like Anxiety GABRA2,GABRG3 
Memory ABL2,CYP19A1,ESR1,IL1RN,LEPR,MTOR 
Abnormal Initiation Of Locomotion CYP19A1,NFATC3,PARK7 
e. SVA_E 
Diseases or Functions Annotation Molecules 
Spatial Learning CREB1,OPHN1,UBR1 
Vertical Rearing CREB1,UBR1 
Discriminatory Learning UBR1 
Aggressive Behaviour Toward Mice OPHN1 
Anxiety CREB1,OPHN1 
Short-Term Memory CREB1 
Addiction Behaviour CREB1 
Memory CREB1,OPHN1 
Place Preference CREB1 
Passive Avoidance Learning UBR1 
f. SVA_F 
Diseases or Functions Annotation Molecules 
Social Behaviour KALRN,OMP,PDE11A 
Long-Term Spatial Reference Memory PSEN1 
Mother Preference OMP 
Social Odour Recognition Memory PDE11A 
Behaviour APLP2,KALRN,LEF1,MYH10,OMP,PARK2,PDE11A,PSEN1 
Associative Memory PSEN1 
g.SVA_F1 
Diseases or Functions Annotation Molecules 
Behaviour ACOT11,ATG7,CYP7B1,MKL1 
Limb Clasping ATG7 
Feeding ACOT11,MKL1 
Nursing MKL1 
Walking ATG7 
 
 
 
 
